Assessment of platelet activation and prothrombotic risk following acute upper gastrointestinal bleeding and bleeding in the context of acute coronary syndromes by Disney, Benjamin Robert
  
 
ASSESSMENT OF PLATELET ACTIVATION AND 
PROTHROMBOTIC RISK FOLLOWING ACUTE UPPER 
GASTROINTESTINAL BLEEDING AND BLEEDING IN THE 
CONTEXT OF ACUTE CORONARY SYNDROMES 
 
 
by 
 
BENJAMIN ROBERT DISNEY 
 
 
A thesis submitted to the University of Birmingham for the degree of 
DOCTOR OF MEDICINE (M.D.) 
 
 
 
 
Institute of Cancer and Genomic Sciences 
The University of Birmingham 
October 2016 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Abstract  
Patients presenting with acute upper gastrointestinal bleeding have an increased incidence of 
cardiovascular events, with mortality invariably related to factors other than the bleeding 
itself, with the majority of deaths related to cardiovascular disease. The Blatchford score is 
used to identify low risk patients suitable for early discharge. Diurnal and seasonal variation 
in acute upper gastrointestinal bleeding has not been addressed in the UK population.  
Patients presenting with bleeding complicating acute coronary syndromes are at an increased 
risk of recurrent cardiovascular events and have higher short-term and long-term mortality 
when compared to patients with uncomplicated acute coronary syndromes. 
This study has shown the preferential use of the Blatchford score in identifying patients 
suitable for early discharge and using a cut-off score of 2 could avoid up to 15% of 
admissions for acute upper gastrointestinal bleeding. The results show significant diurnal and 
seasonal variation in the presentation of acute upper gastrointestinal bleeding with fewer 
admissions in the winter months and a higher proportion of patients presented in the 12:01-
18:00 time period. 
This study has shown an increase in levels of platelet activation and prothrombotic markers 
(d-dimer and vWF) in the acute upper gastrointestinal bleeding population, which may help 
explain the risk of these patients developing future cardiovascular events. No such findings 
were seen in the acute coronary syndromes complicated by bleeding group which may in part 
be due to the treatments patients received or due to the small numbers of patients recruited. 
These novel findings may help explain the excess of cardiovascular mortality in patients with 
presenting upper gastrointestinal bleeding and give a biological rationale to restarting 
antiplatelet agents early in these patients. Further studies are required to confirm and further 
investigate these findings. 
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CHAPTER 1 – INTRODUCTION AND BACKGROUND 
 
1.1 Overview 
This chapter provides an introduction to, and discusses in detail, two separate but related 
areas. These are the clinical nature, importance and management of two types of bleeding; 
acute upper gastrointestinal bleeding and bleeding in the context of acute coronary 
syndromes, and the role of platelets and prothrombotic markers in these conditions.  
 
1.2 Non-variceal Acute Upper Gastrointestinal Bleeding 
1.2.1 Introduction to non-variceal upper gastrointestinal bleeding  
Acute upper gastrointestinal bleeding (AUGIB) is defined in table 1.1; it is generally the 
vomiting of blood and/or the passage of blood or melaena via the rectum (Hearnshaw et al 
2010). Gastrointestinal bleeding can be split into upper or lower in origin, with upper 
gastrointestinal bleeding being caused by a lesion proximal to the ligament of Treitz. AUGIB 
is a common medical emergency and is associated with significant morbidity and mortality 
(Klein and Gralnek 2015). It can be split into variceal (associated with chronic liver disease) 
and non-variceal in its origin (associated with anti-platelet medication and helicobacter pylori 
infection) (Rotondano 2014).  
In this chapter, only non-variceal AUGIB will be discussed for the following reasons. 
Patients who suffer from variceal bleeding generally have chronic liver disease and as such, 
represent a different subset of patients with a very different risk-factor profile, specific 
pharmacological treatments and disease-related mortality. Variceal bleeding is not commonly 
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triggered by anti-platelet therapy and does not commonly complicate acute coronary 
syndromes (ACS). Many studies show that chronic liver disease itself causes abnormal 
platelet function (Ogasawara et al 2005; Panasiuk et al 2001; Panasiuk et al 2005; Tacke et al 
2003; Vardareli et al 2007; Witters et al 2008). Given that this study focuses on the role of 
platelets in the context of bleeding, variceal bleeding will not be discussed.  
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Table 1.1 Definitions relating to acute upper gastrointestinal bleeding (adapted from 
Hearnshaw et al 2010) 
Acute upper 
gastrointestinal 
bleed (AUGIB) 
Haematemesis, the passage of melaena and/or firm clinical or 
laboratory evidence of acute blood loss from the UGI tract within the 
previous 10 days. The origin of bleeding is proximal to the ligament 
of Treitz. 
Haematemesis Vomiting of blood or blood clots. Occasionally this can be caused 
after swallowing blood from a source in the nasopharynx. Coffee-
ground vomitus refers to the vomiting of black material which is 
assumed to be blood. 
Melaena The passage of black tarry stools. 
Haematochezia The passage of fresh or altered blood per rectum. Usually due to 
colonic bleeding, occasionally caused by profuse AUGIB. 
High risk stigmata 
on OGD 
Red blood in the UGI tract, spurting or oozing, visible vessel, 
adherent clot for all diagnoses; red spot, wheal, marking or nipple 
sign on varix/varices. 
Rebleeding Further haematemesis, passage of fresh melaena, continuing or 
recurring hypotension and tachycardia ± fall in haemoglobin after 
the first endoscopy 
All-cause mortality Death occurring within the hospital admission up to 30 days post 
index AUGIB.   
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1.2.2 Epidemiology of acute upper gastrointestinal bleeding 
Hospital admission due to AUGIB is significant problem with important implications for 
health economics (Campbell et al 2015; Cryer et al 2010). In the USA, the estimated 
incidence of AUGIB rates is 150 cases per 100000 population which translates to 
approximately 400000 admissions per annum (Lewis et al 2002). Across Europe the 
incidence varies between 50-170 per 100000 population (Blatchford et al 1997; Button et al 
2011; Hearnshaw et al 2010a; Rockall et al 1995). The incidence in the UK has remained 
stable over the past decade, however, elsewhere in Europe hospitalisations have decreased 
(Button et al 2011; Lanas et al 2011). The incidence of AUGIB secondary to peptic ulcer 
disease only is between 19-57 per 100000 population (Lau et al 2011). 
In the UK, AUGIB accounts for over 9000 deaths per annum (Crooks et al 2009). Mortality 
in the context of AUGIB is 8.2-13.1% (Blatchford et al 1997; Button et al 2011; Crooks et al 
2011). There is evidence showing that 28-day mortality has reduced over time (1999-2007) 
for non-variceal haemorrhage from 14.7% to 13.1% and for variceal haemorrhage from 
24.6% to 20.9% (Crooks et al 2011). Long term outcomes following peptic ulcer bleeding are 
poor. Mortality rates following peptic ulcer bleeding have been reported as 28.7% at 1-year 
and 46.8% at 5-years (Imhof et al 2007). Other studies reported 29% mortality following 
gastric ulcer or peptic ulcer bleeding (Hudson et al 1995; Smart and Langman 1986). 
There is some evidence that patients presenting at the weekend have worse mortality 
outcomes – 13% higher for weekend admissions and 41% higher for those admitted during a 
bank holiday (Button et al 2011). In-patients that develop AUGIB have a higher mortality, 
26%, compared with 6.8% in new admissions with AUGIB (Hearnshaw et al 2011). 
Despite advances in pharmacological and endotherapy mortality remains high. This is likely 
to be accounted for by an aging population with increasingly complex, and multiple, co-
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morbidities (Klein and Gralnek 2015). The median age of patients presenting with AUGIB is 
68 years (IQR 49-81) (Hearnshaw et al 2011). Sixty percent of patients with peptic ulcer 
disease are above the age of 60 and approximately 20-25% above the age of 80 (Hearnshaw 
et al 2011; Rockall et al 1995; Ohmann et al 2005). Those patients found to have varices or 
malignancy at endoscopy have the highest rates of in-hospital mortality, 15 and 17% 
respectively (Hearnshaw et al 2011). 
The cause of death in patients suffering from peptic ulcer disease bleeding is not necessarily 
from the bleeding itself. A study from Hong Kong found that of the patients that died (6.2%), 
only 18.4% of those died from a bleeding-related cause. Non-bleeding related mortality was 
due to cardiac disease (13.5%), pulmonary disease (23.5%), multiorgan failure (23.9%) and 
terminal malignancy (33.7%), all of which may be complicated by a bleeding event (Sung et 
al 2010a). The association between cardiovascular disease and AUGIB will be discussed later 
(section 1.2.11). 
Many medical conditions show diurnal and seasonal variation. Examples include acute 
coronary syndromes, heart failure and stroke (Marsh et al 1990; Muller et al 1985; Muller et 
al 1987; Quyyami 1990; Tofler et al 1987; Willich et al 1987; Zarich et al 1994). Diurnal and 
seasonal variations in AUGIB have been previously described but the results are conflicting. 
A European study found biphasic peaks in peptic ulcer bleeding with haematemesis incidence 
peaking at both 6:45AM and 6:45PM (Minoli et al 1994). However, data from China has 
highlighted a diurnal variation in the presentation of AUGIB with a peak incidence in the 
nighttime hours (Du et al 2010). Several authors have looked for seasonal differences in 
AUGIB with conflicting results. Results from China suggest an increased incidence during 
colder months (December to April) and similar results are also seen in Israel (Du et al 2010; 
Stermer et al 1995). The observation of a decrease in presentation during winter is consistent 
with a previous European based study (Thomopoulos et al 1997). 
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1.2.3 Aetiology and pathophysiology of non-variceal acute upper gastrointestinal 
bleeding 
Helicobacter pylori (H. pylori) is the main aetiological factor in the development of peptic 
ulcer disease. being responsible for up to 90% of duodenal and 70% gastric ulcers (Marshall 
et al 1985). In bleeding peptic ulcers the prevalence of H. pylori is between 55-68% (Tang et 
al 2009). One study suggests the prevalence is as high as 92.4% in bleeding duodenal ulcers, 
84% in non-steroidal anti-inflammatory drugs (NSAIDS) users and 96.7% in non-NSAID 
users (Gisbert et al 2001). 
The other factor associated with the development of oesophago-, gastro-, duoden- itis and 
peptic ulcer disease is the use of NSAIDS. Different NSAIDS have differing risk profiles for 
the development of AUGIB (Langman et al 1994): 
• Low risk – ibuprofen (OR 2.0, 95% CI 1.4-2.8) and diclofenac (OR 4.2 95% CI 2.6-
6.8) 
• Intermediate risk – indomethacin (OR 11.3, 95% CI 6.3-20.3), naproxen (OR 9.1, 
95% CI 5.5-15.1) and piroxicam (OR 13.7, 95% CI 7.1-26.3) 
• High risk – azapropaone (OR 31.5, 95% CI 10.3-96.9) and ketoprofen (OR 23.7, 95% 
CI 7.6-74.2)  
H. pylori infection and NSAID use are independent risk factors for peptic ulcer disease. 
There is, however, synergism for the development of peptic ulcer bleeding between H. pylori 
infection and NSAID use (Huang et al 2002). This meta-analysis found NSAID use more 
common in patients with AUGIB than controls, OR 4.85 (95% CI 3.77-6.23). H. pylori 
infection was again found to be more common than in controls, OR 1.79 (95% CI 0.97-3.32. 
7 
 
However, patients taking NSAIDS and who were H. pylori positive had an additive effect for 
risk of AUGIB with an OR 6.13 (95% CI 3.93-9.56) (Huang et al 2002). 
Despite these causative factors between 11-44% of peptic ulcers are not associated with H. 
pylori infection or the use of NSAIDS (Hung et al 2005). However, in H. pylori and NSAID 
negative ulcers, the cause is surreptitious NSAID use in up to 60% of cases. Other 
medications associated with peptic ulcer disease include bisphosphonates, mycophenalate and 
potassium chloride. Other rare causes include Zollinger-Ellison syndrome, helicobacter 
heilmanii, cytomegalovirus, systemic mastocytosis, Crohn’s disease and idiopathic (Quan et 
al 2002). Other risk factors for the development of peptic ulcer disease are corticosteroid use, 
oral anticoagulation, previous peptic ulcer, dyspepsia within the previous year, heart failure, 
diabetes and current smoking (Weil et al 2000). 
The underlying cause of AUGIB found on upper GI endoscopy is most commonly peptic 
ulcer disease, which accounts for one third of all bleeds (Hearnshaw et al 2011). Other causes 
include oesophagitis and gastritis. Interesting no abnormality is found in up to 17% of 
endoscopies performed for AUGIB (Hearnshaw et al 2011). Table 1.2 has further details of 
the abnormality found on endoscopy in patients presenting with AUGIB. 
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Table 1.2 Abnormality found at endoscopy in patients presenting with acute upper 
gastrointestinal bleeding (Hearnshaw et al 2011)  
Cause of bleeding Frequency (% found at endoscopy) 
Peptic ulcer 36.0 
Oesophagitis 24 
Gastritis or erosions 22 
Erosive duodenitis 13 
Varices 11.0 
Portal hypertensive gastropathy 7 
Malignancy 3.7 
Mallory Weiss tear 4.3 
Other (vascular ectasia, haemobilia) 2.6 
No abnormality seen 17 
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1.2.4 Management of acute upper gastrointestinal bleeding 
It should be noted that acute upper GI bleeding is a medical emergency associated with 
significant mortality (Gralnek et al 2015). As such, the most important initial management of 
a patient presenting with upper GI bleeding involves urgent assessment and risk stratification, 
and prompt fluid resuscitation (Gralnek et al 2015). Once the patient has been adequately 
resuscitated an upper GI endoscopy can be considered. Endoscopic therapy can be used to 
treat the cause of bleeding, however, if this fails to control the bleeding then interventional 
radiology or surgery may be required. 
 
1.2.4.1 Pre-endoscopic management of acute upper gastrointestinal bleeding 
Resuscitation 
All patients should receive adequate fluid resuscitation (Gralnek et al 2015). Initially the 
blood pressure should be maintained with infusion of crystalloid. AUGIB is a common 
indication for red blood cell (RBC) transfusion, and accounts for 14% of all RBC units 
transfused in the UK (Wallis et al 2006). Blood transfusions are given to 43% of patients 
hospitalised with AUGIB in the UK (Hearnshaw et al 2011).  
Guidelines on the use of RBC transfusion vary. Current UK guidelines recommend RBC 
transfusion after 30-40% of the circulating volume has been lost, based on a reduced systolic 
and diastolic blood pressure and a tachycardia of greater than 120bpm (SIGN 2008). 
The American Society of Gastrointestinal Endoscopy (ASGE) guidelines recommend ‘that 
packed red blood cells should be transfused in patients with evidence of ongoing or active 
blood loss who have experienced significant blood loss or cardiac ischaemia’ (ASGE 2004). 
The latest International Consensus suggests a blood transfusion if the haemoglobin is less 
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than 70 g/L, with a target of 70-90 g/L in the absence of tissue hypoperfusion, coronary artery 
disease or acute haemorrhage (Barkun et al 2010; Gralnek et al 2015). International 
guidelines recommend considering transfusion when haemoglobin levels are less than 80 g/L 
or when cardiovascular symptoms develop in haemodynamically stable patients with pre-
existing cardiovascular disease (Carson et al 2012).  
The benefit of RBC transfusion in a massive AUGIB can be lifesaving; however, there is 
evidence to suggest that early transfusion in less severe bleeding can be harmful (Fabricius et 
al 2016; Hearnshaw et al 2010b; Subramaniam et al 2016). Recent evidence suggests early 
transfusion is associated with a two-fold risk of rebleeding (OR 2.26, 95% CI 1.76-2.90) and 
a 28% increase in mortality (OR 1.28, 95% CI 0.94-1.74) (Hearnshaw et al 2010b). Indeed a 
Cochrane review reports an increase in rebleeding and mortality rates in the transfusion arms 
of several studies; however, the data is limited by small numbers (Jairath et al 2010). This 
problem has been overcome by Villanueva and colleagues who investigated liberal and 
restrictive transfusion strategies for AUGIB (Villanueva et al 2013). The restrictive strategy 
meant blood transfusion occurred when the haemoglobin was less than 70 g/L, whereas the 
threshold was 90 g/L in the liberal arm. The restrictive group had fewer adverse events such 
as transfusion reactions and cardiac events (40% versus 48%), rebleeding (10% versus 16%, 
HR 0.68, 95% CI 0.47-0.98) and most importantly reduced mortality for the 45 days 
following admission (5% versus 9%, HR for death 0.55, 95% CI 0.33-0.92) (Villanueva et al 
2013).  The most recent National Institute for Health and Care Excellence (NICE) guidelines 
for blood transfusion endorse the threshold of 70 g/L with a target haemoglobin of 70-90 g/L 
(NICE 2015). 
In practice things are not as black or white as some of the evidence suggests (i.e. choosing to 
transfuse a patient if the haemoglobin is less than 70 g/L). A more pragmatic view is taken in 
the latest NICE guidelines on AUGIB which recommend basing decisions on blood 
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transfusion on the full clinical picture, recognising that over-transfusion may be as damaging 
as under-transfusion (NICE 2012). 
Platelet transfusion should be offered to patients who are actively bleeding and have a platelet 
count of less than 50 x 109/L. The appropriate use of platelet transfusion has been associated 
with a reduction in the need for re-endoscopy (Fabricius et al 2016). Fresh frozen plasma 
should be given to patients with either (i) a fibrinogen level of less than 1 g/L or (ii) a 
prothrombin time or activated partial thromboplastin time of greater than 1.5 times normal. 
Prothrombin complex concentrate should be offered to patients who are taking warfarin and 
are actively bleeding (NICE 2012). 
 
1.2.5 Pre-endoscopy risk assessment 
Scoring systems have been developed to highlight those patients who are likely to require an 
intervention or are at risk of rebleeding and death. The Rockall and Blatchford scores are the 
most well recognised such scores (Rockall et al 1996; Blatchford et al 2000). 
The Rockall scoring system was devised to identify patients at risk of death or rebleeding 
based upon a combination of clinical and endoscopic findings (Rockall et al 1996a). The 
score is split into pre-endoscopic Rockall score which is based upon age, presence of shock 
and co-morbidity, whilst the post-endoscopic score also takes into account endoscopic 
diagnosis and stigmata of recent haemorrhage (see table 1.3). The maximum score is 7 pre-
endoscopy and 11 post-endoscopy.  A score of 0 pre-endoscopy would be a patient under the 
age of 60 years with no signs of shock and no significant co-morbidity. In this study, 15% of 
patients had an initial score of 0 which signifies a low risk of death (0.2%) or rebleeding 
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(0.2%) and these patients should be considered for discharge and early outpatient endoscopy 
(Rockall et al 1996b).   
 
Mortality rates increase with increasing pre-endoscopic score: 
• Rockall score 0 – death 0.2% 
• Rockall score 1 – death 2.4% 
• Rockall score 2 – death 5.6% 
• Rockall score 5 – death 39.6% 
• Rockall score 7 – death 50% 
Of those patients who undergo endoscopy, a Rockall score ≤ 2 is associated with a 4.3% risk 
of rebleeding and 0.1% risk of death (Rockall et al 1996b). These patients should be 
considered for early discharge. 
The Rockall score has been validated as a good tool for stratifying patients into high- and 
low-risk for mortality, however, it is less useful in the prediction of rebleeding (Vreeburg et 
al 1999). 
The Glasgow Blatchford Scoring (GBS) system was developed to predict those patients with 
AUGIB that would require intervention (i.e. blood transfusion, endoscopic therapy or 
surgery) or death (Blatchford et al 2000, Stanley et al 2009). The score was developed in 
Scotland with data from 1748 patients presenting with AUGIB (Blatchford et al 2000). 
The advantage of the Blatchford score over the Rockall score is that it is based on simple 
variables from a patient’s history, examination and laboratory results (see table 1.4), whereas 
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the Rockall score is not complete until endoscopic findings are known, often meaning 
patients are kept in hospital unnecessarily.  
On the results of simple laboratory and clinical data a GBS score between 0 and 23 is 
derived.  A score of 0 identifies a group of patients with a very low-risk of requiring an 
intervention – 0.5% (Blatchford et al 2000). 
Up to 16% of patients admitted with an AUGIB have a Blatchford score of 0 and up to 28% 
have a Rockall score of 0 (Stanley et al 2009). There is evidence to support the Blatchford 
score being more useful than the Rockall score for predicting low-risk patients who do not 
need therapeutic endoscopy and who may be suitable for outpatient management (Stanley et 
al 2009, Pang et al 2010). Of the patients in one study with a Blatchford score of 0, no 
interventions and no deaths were recorded. However, 17% of those with an initial Rockall 
score of 0 required an intervention and there was 1 death (Stanley et al 2009).  
A study of low-risk AUGIB individuals, defined as GBS ≤ 2 and age < 70, identified 34.2% 
of all patients presenting with AUGIB of whom 10.5% were managed safely as outpatients 
(Stephens et al 2009). Other studies have also looked at a GBS of ≤ 2 to define low-risk 
(Masaoka et al 2006; Srirajaskanthan et al 2010). To assess the validity of the GBS at 
separating low and high-risk groups, receiver-operator characteristic (ROC) curves were 
plotted. The GBS had an area under ROC curve of 0.96 (95% CI 0.95–1.00). When a cut-off 
value of ≥ 3 was used, sensitivity and specificity of GBS for identifying high risk bleeds was 
100% and 68%. Thus at a cut-off value of ≤ 2 the GBS is useful for distinguishing those 
patients with a low risk UGI bleed (Srirajaskanthan et al 2010). Despite this evidence current 
international guidelines define high-risk patients as those with a GBS ≥ 1 (Sung et al 2011). 
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The latest NICE guidelines suggest formal risk scoring in all patients presenting with 
AUGIB; the Blatchford score being used at first assessment and the Rockall score once an 
endoscopy has been performed (NICE 2012). 
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Table 1.3 Rockall Scoring system 
Variable 0 1 2 3 
Age < 60 years 60-79 years ≥ 80 years  
Shock No shock 
SBP ≥ 100mm 
Hg, pulse < 100 
bpm 
Tachycardia 
SBP ≥ 100mm 
Hg, pulse > 100 
bpm  
Hypotension 
SBP < 100mm 
Hg 
 
Co-morbidity None  Cardiac failure, 
IHD 
Renal failure, 
liver failure, 
metastatic 
malignancy 
Diagnosis Mallory-Weiss 
tear, no lesion and 
no SRH 
All other 
diagnoses 
Malignancy of 
upper GI tract 
 
Major SRH None or dark spot 
only 
 Blood in upper 
GI tract, 
adherent clot, 
visible or 
spurting vessel 
 
 
SBP – systolic blood pressure; IHD – ischaemic heart disease; SRH – stigmata of recent 
haemorrhage 
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Table 1.4 Glasgow Blatchford Score 
Clinical Variable Score Value 
Blood urea (mmol/L)   
6.5-7.9 2 
8.0-9.9 3 
10.0-25.0 4 
>25.0 6 
Haemoglobin for men (g/L)   
120-129 1 
110-119 3 
<100 6 
Haemoglobin for women (g/L)   
100-119 1 
<100 6 
Systolic BP (mm Hg)   
100-109 1 
90-99 2 
<90 3 
Other markers   
Pulse ≥ 100/min 1 
Melaena 1 
Syncope 2 
Hepatic disease* 2 
Cardiac failure† 2 
 
*Known history, or clinical and laboratory evidence, of chronic or acute liver disease. 
†Known history, or clinical and echocardiographic evidence of, cardiac failure. 
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1.2.6 Pharmacological therapy 
There is evidence suggesting that the use of pharmacological therapy to increase gastric pH 
by inhibiting gastric acid secretion promotes clot formation, stabilises the clot and perhaps 
hastens the healing of lesions (Barkun et al 2006). This is based upon historic in vitro data 
that suggest a pH above 6 is needed to inactivate pepsin (Green et al 1978). A more recent 
study found that by increasing the intragastric pH to ≥ 6.4, by proton pump inhibitor (PPI) 
therapy, gastric mucosal bleeding time was reduced (Li et al 2000). 
• Proton pump Inhibitors (PPI) therapy. It appears to be commonplace for patients 
to receive a PPI upon presentation with AUGIB, with up to 89% of patients receiving 
intravenous PPI prior to endoscopy (Enns et al, 2004; Hearnshaw et al 2010a). However, the 
evidence for such an approach is lacking. One randomised controlled trial (RCT) assigned 
patients to receive either omeprazole (80mg IV bolus followed by 8mg per hour) or placebo 
(Lau et al 2007). Those in the omeprazole group had a reduced need for endoscopic therapy 
(19.1% versus 28.4%, P=0.007), fewer actively bleeding ulcers and more ulcers with a clean 
base. However, there were no differences in transfusion need, rebleeding or death (Lau et al 
2007).  Similar findings were observed in a Canadian study (Andrews et al 2005). Indeed, a 
recent Cochrane meta-analysis of 6 RCTs reached a similar conclusion (Sreedharan et al 
2010). PPI treatment reduced the need for endoscopic therapy at initial endoscopy (OR 0.68, 
95% CI 0.50-0.93). However, no significant differences were seen in mortality (OR 1.12, 
95% CI 0.72-1.73), rebleeding (OR 0.81, 95% CI 0.61-1.09) or need for surgery (OR 0.96, 
95% CI 0.68-1.35) (Sreedharan et al 2010). Interestingly, the use of pre-endoscopy PPI is 
cost-effective as it reduces the need for endoscopic therapy. However, this evidence is based 
on Asian population studies, which usually have a different case mix to western centres (less 
alcohol and different parietal cell mass) (Tsoi et al 2008). Current UK guidelines do not 
support the use of PPIs prior to endoscopy (SIGN 2008; NICE 2012). 
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• Prokinetic agents. The prokinetic erythromycin (a motilin receptor agonist) can be 
given prior to endoscopy in the case of AUGIB to stimulate gastrointestinal motility (Peeters 
et al 1989). Erythromycin given intravenously prior to endoscopy does improve endoscopic 
examination with improved rates of mucosal visualisation and reduces the numbers of clots, 
but does not impact important clinical outcomes – mortality, ability to identify source of 
bleed, length of hospital stay and need for blood transfusion or surgery (Carbonell et al 2006; 
Coffin et al 2002; Frossard et al 2002; Pateron et al 2011). This approach, however, has been 
shown to be cost-effective using computer modelling (Winstead et al 2010).  
• Tranexamic acid. The use of tranexamic acid in AUGIB dates back almost 40 years 
when several small studies were carried out with conflicting results (Barer et al 1983; Biggs 
et al 1979; Engqvist et al 1979). Recent Cochrane reviews concluded that tranexamic acid 
may reduce mortality associated with AUGIB although due to the high drop out in previous 
trials further study is required and routine use cannot be currently recommended (Bennett et 
al 2014; Gluud et al 2012). It is not currently recommended for routine use in any guidelines. 
However, this may change when the results of the ongoing HALT-IT trial, a randomised 
controlled trial of the effect of tranexamic acid in AUGIB, become available (Roberts et al 
2014). 
  
1.2.7 Endoscopy for acute upper gastrointestinal bleeding 
Endoscopy is the primary diagnostic and therapeutic tool for patients with AUGIB. 
Endoscopy should take place after adequate resuscitation or in those patients with ongoing 
bleeding (Gralnek et al 2015). Endoscopic therapy in AUGIB has reduced transfusion 
requirements, rebleeding rates, the need for surgery, mortality and length of hospital stay 
(Cappell et al 2008; Kovacs et al 2008). 
19 
 
Endoscopy within 24 hours of presentation (early endoscopy) allows for early risk 
stratification, improves patients outcomes for those with high-risk lesions found on 
endoscopy and allows for the early (and safe) discharge of patients with low risk lesions 
(Barkun et al 2010). UK and international guidelines advocate endoscopy within 24 hours of 
admission (Barkun et al 2010; NICE 2012; SIGN 2008). However, there are conflicting 
results when it comes to the timing of endoscopy. In one study, very early endoscopy (i.e. 
within 12 hours) did not improve the clinical outcomes of mortality, need for surgery or 
reduce transfusion rates (Tsoi et al 2009) in all comers with AUGIB. However, another study 
found that delay to endoscopy was associated with an increase in mortality (Wysocki et al 
2012). Furthermore, in high-risk patients, as defined by a GBS ≥ 12, endoscopy within 13 
hours of presentation has been associated with a reduction in mortality (Lim et al 2011). 
Although a more recent study has demonstrated that very early endoscopy (within 12 hours) 
in patients with a GBS <12 is associated with an increase in a composite outcome of death, 
rebleeding and the need for surgical or radiological intervention (Kumar et al 2016). In the 
UK, unfortunately only 50% of patients undergo endoscopy within 24 hours of presentation 
with an AUGIB (Hearnshaw et al 2010a). Endoscopy may be delayed if the patient is too 
unwell or due to co-morbid conditions such as recent ACS. The timing of endoscopy in this 
situation is discussed elsewhere (see section 1.3.8).  
Generally, endoscopy should take place after adequate fluid resuscitation as this is associated 
with a reduction in cardiopulmonary complications (Barkun et al 2003; Kumar et al 2016). In 
certain situations where a patient is unstable with ongoing bleeding and signs of shock, early 
endoscopy should take place whilst the patient is being resuscitated. Early endoscopic 
therapy in this situation is associated with better patient outcomes (Barkun et al 2010; Kumar 
et al 2016; Lim et al 2011). Endotracheal intubation to prevent aspiration is recommended for 
patients with ongoing haematemesis or altered mental status (Ghassemi et al 2009). 
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Endoscopy should take place in a controlled environment with a specialist nursing team who 
are familiar with endoscopic techniques. 
Peptic ulcers are a common cause found on endoscopy in patients with AUGIB although not 
all ulcers will warrant endoscopic therapy. The need for endoscopic therapy can be 
categorised by stigmata of recent haemorrhage (SRH). These are split into high and low-risk 
SRH, based on risk of rebleeding, and the endoscopic management of each lesion varies. 
Table 1.5 shows SRH and the risk of recurrent bleeding (Enestvedt et al 2008; Kovacs et al 
2007; Laine and Peterson 1994). 
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Table 1.5 Stigmata of recent haemorrhage and risk of bleeding, surgery and mortality 
in peptic ulcer disease 
Stigmata of 
recent 
haemorrhage 
Forrest 
classification 
Prevalence Further 
bleeding 
Surgery for 
bleeding 
Mortality 
Active 
spurting 
bleeding 
 
IA 12% (spurting 
and oozing) 
55% (spurting 
and oozing) 
35% (spurting 
and oozing) 
11% (spurting 
and oozing) 
Active oozing 
bleeding 
 
IB     
Non-bleeding 
visible vessel 
 
IIA 8% 43% 34% 11% 
Adherent clot 
 
IIB 8% 22% 10% 7% 
Flat 
pigmented 
spot 
 
IIC 16% 10% 6% 3% 
Clean base III 55% 5% 0.5% 2% 
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1.2.8 Endoscopic therapy  
The endoscopist has a myriad of options for therapeutic endoscopy and the modality used is 
user dependent based on familiarity with the various techniques. The goal is to prevent 
continued bleeding and reduce the risk of rebleeding. Therapeutic endoscopy in patients with 
a peptic ulcer is not indicated for low-risk stigmata and should be reserved for those with 
high-risk stigmata (Barkun et al 2010).  
• Peptic ulcer disease. As already mentioned the management of AUGIB due to a 
peptic ulcer does not necessarily require endoscopic therapy. This should be reserved for 
patients with high risk SRH; those with active spurting or oozing or a non-bleeding visible 
vessel (Laine and Jensen 2012). The therapeutic options available to an endoscopist are 
adrenaline injection, mechanical clips, thermocoagulation, Hemospray and sclerosant 
injection. Adrenaline halts bleeding by 3 mechanisms: local tamponade by the injection of 
fluid, by vasoconstriction and by thrombosis (Kubba et al 1996).  
Current national and international guidelines recommend the use of adrenaline plus another 
modality (i.e. clips or thermocoagulation) for endoscopic haemostatic therapy for patients 
with high-risk stigmata – active bleeding, non-bleeding visible vessel and an adherent clot 
(Barkun et al 2010; SIGN 2008, NICE 2012). Adrenaline should not be used alone, as it is 
inferior to both combination therapy and thermal or clips alone (Barkun et al 2009; Barkun et 
al 2010). One meta-analysis compared injection plus clips to injection therapy alone. Dual 
therapy with injection plus clips was superior in haemostasis to injection alone (88.5% versus 
78.1%; RR 1.13, 95% CI 1.03-1.23) leading to a reduction in the need for surgery, however, 
no difference in mortality was observed (Sung et al 2007). A second meta-analysis found the 
addition of a second endoscopic modality, in addition to adrenaline injection, reduced 
rebleeding (18.4% to 10.6%), surgery (11.3% to 7.6%) and more importantly, mortality was 
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reduced from 5.1% to 2.1% (OR 0.51; 95% CI 0.31-0.84) (Calvet et al 2004). A subsequent 
Cochrane review found that adding a second modality to adrenaline injection reduced 
rebleeding (OR 0.51, 95% CI 0.39-0.66), need for surgery (OR 0.63, 95% CI 0.45-0.89) and 
mortality (OR 0.50, 95% CI 0.30-0.82) (Vergara et al 2007). 
One area of controversy with regards to peptic ulcers is what to do with an adherent clot. 
Many endoscopists adopt a more cautious approach, leaving the clot in situ and continuing 
pharmacologic therapy, whereas ‘the brave’ remove the clot and apply treatment to the ulcer. 
Rebleeding rates for ulcers with an adherent clot vary between 10-40% and after clot removal 
is only 8% (Laine et al 1994, Laine et al 1996). The findings after clot removal are a clean 
ulcer base in 57%, flat spot 11%, non-bleeding visible vessel 13%, oozing 13%, and spurting 
2% (Laine et al 1996). One randomised study compared a combination of endoscopic therapy 
and omeprazole infusion (80 mg bolus followed by 8 mg/hour) to omeprazole alone (Sung et 
al 2003). In this study, patients with adherent clot had this actively removed using irrigation 
and a mini-snare, and the underlying vessels were treated with thermocoagulation. Recurrent 
bleeding within 30 days was 11.6% in those treated with omeprazole alone and 1.1% 
rebleeding in the dual therapy group (P=0.009). This has been confirmed by further studies 
(Bini et al 2003; Bleau et al 2002; Jensen et al 2002). In these studies patients treated with 
endoscopic removal of the clot and endoscopic therapy had lower rates of rebleeding, 
decreased length of hospital stay and lower numbers of RBC transfusion. A subsequent meta-
analysis drew the same conclusions (RR rebleeding of 0.35, 95% CI 0.14-0.83) (Kahi et al 
2005). International guidelines recommend that when an adherent clot is present that 
endoscopic removal of the clot should be considered so that the underlying vessel can be 
treated (Gralnek et al 2015; Hwang et al 2012; Laine and Jensen 2012). 
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Figure 1.1 Management algorithm for the acute phase management of acute upper 
gastrointestinal bleeding due to peptic ulcer. This shows the algorithm of endoscopic 
therapy for high-risk endoscopic features, the need for subsequent intravenous PPI therapy 
and options should rebleeding occur. 
25 
 
1.2.9 Post-endoscopy management of acute upper gastrointestinal bleeding 
• Proton pump inhibitors. The basis of using PPIs is their effect on intragastric pH. 
Gastric acid plays an important role in impairing haemostasis and causing clot lysis (Laine et 
al 2008). Raising the pH above 6 helps stabilise the clot by facilitating platelet aggregation 
(Green et al 1978). High-dose omeprazole can neutralise intragastric pH. An initial bolus 
followed by a constant intravenous infusion of omeprazole increases the intragastric pH 
above 6 rapidly and maintains this for the majority of a 24 hour period (Labenz et al 1997). 
The elimination half-life of oral PPIs is approximately 1 hour meaning that new proton 
pumps can produce acid and therefore an intravenous infusion may be preferential to 
maintain a high gastric pH (Laine et al 2008). A newer study correlated the findings of Laine 
et al and confirmed that the PPIs omeprazole, pantoprazole and rabeprazole given either 
orally or intravenously raise the intragastric pH above 6, significantly higher than placebo 
where a pH of 2.04 was seen (Javid et al 2009).  
There is no doubt about the benefit of high dose intravenous PPI therapy post-endoscopy in 
patients with high-risk lesions found at endoscopy. Previous studies have shown that 
rebleeding is most common within the first 72 hours after endoscopy (Laine et al 1994). This 
gives the rationale to maintain intragastric pH above 6 for this period.  A randomised double-
blind study comparing high-dose intravenous omeprazole with placebo following endoscopic 
therapy for peptic ulcer bleeding found significantly reduced rates of rebleeding in the PPI 
group (Lau et al 2000). Of the 240 patients enrolled (120 in each group), rebleeding within 30 
days occurred in 6.7% and 22.5% in the PPI and placebo groups respectively (HR 3.9, 95% 
CI 1.7-9.0). The PPI cohort had lower transfusion requirements and shorter duration of stay. 
Mortality was lower in the PPI group, but not significantly (P=0.14). This study was carried 
out in a predominately Asian population and cannot necessarily be applicable to a Caucasian 
population (Asians have a smaller parietal cell mass and tend to be slow metabolisers). A 
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newer study with a cohort of 85% Caucasians, compared intravenous esomeprazole or 
placebo following endoscopic therapy for patients with peptic ulcer bleeding and high-risk 
SRH (Sung et al 2009). The rate of rebleeding was significantly lower in the group 
randomised to esomeprazole (P=0.026), although it found that surgery and mortality rates 
were unchanged.  
The benefit of a PPI infusion in this setting has been confirmed by various systematic reviews 
and meta-analyses, with this strategy also found to be cost effective (Barkun et al 2004; 
Barkun et al 2010; Leontiadis et al 2005; Leontiadis et al 2006; Leontiadis et al 2007; 
Leontiadis et al 2010). Newer evidence, from a meta-analysis studying intermittent versus 
continuous PPI infusion, found similar results in terms of rebleeding, mortality and length of 
stay between the two approaches (Sachar et al 2014). Future guidelines may take into account 
these findings which would be both cost and resource saving. 
An oral PPI can be commenced once the 72 hour infusion has been finished. If H. Pylori is 
confirmed, and eradicated, an additional 3 week course of PPI is needed to ensure ulcer 
healing (Liu et al 2003). A maintenance dose is not needed unless ulcerogenic medications 
are to be continued. 
• Helicobacter pylori eradication. The detection, and subsequent eradication, of H. 
pylori is important in the management of AUGIB. H. pylori is the main cause of peptic 
ulcers. Successful eradication is associated with reduced ulcer recurrence: 6% vs. 67% for 
patients with duodenal ulcers; 4% vs. 59% for patients with gastric ulcers (Hopkins et al 
1996). H. pylori eradication within 6 months of a diagnosis of peptic ulcer was associated 
with reduced hospitalisation with major ulcer events (HR 0.57, 95% CI 0.54-0.59) (Hsaio et 
al 2011). Eradication of H. pylori is more effective than anti-secretory medication (H2RA or 
PPI) non-eradication therapy in preventing rebleeding from peptic ulcers (4.5% versus 
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23.7%; OR 0.18, 95% CI 0.09-0.37) (Gisbert et al 2004; Gisbert et al 2004). One study from 
Finland found that H. Pylori eradication therapy alone may be sufficient in the treatment of 
H. Pylori positive ulcers without the need for PPI therapy (Arkkila et al 2005). Current 
guidelines suggest a 14 day eradication regimen (Fallone et al 2016; Chey et al 2017). 
It should be noted, however, that the detection of H. Pylori in the setting of a bleeding ulcer 
can be problematic. Studies have shown the rapid urease tests sensitivity to detect H. Pylori is 
reduced with increasing numbers of false-negatives in the context of bleeding peptic ulcers 
(Romero Gómez et al 1998; Tang et al 2009).  A meta-analysis found biopsy-based methods 
of H. Pylori detection such as rapid urease test, histology and culture have a low sensitivity 
but high specificity in patients with AUGIB (Gisbert et al 2006).  Current guidelines suggest 
caution of negative results in the acute setting and the need for repeated testing (Barkun et al 
2010). 
• NSAIDS. In patients suffering from arthritis or cardiovascular disease there may be a 
strong indication for continuing ulcerogenic treatment. In these cases the benefits and risks of 
therapy must be assessed in each individual patient.  
With respect to NSAIDS and cyclooxygenase-2 (COX-2) inhibitors current evidence suggests 
a strong link with recurrent bleeding. One study compared celecoxib to diclofenac plus PPI in 
patients presenting with peptic ulcer bleeding. After 6 months recurrent bleeding was 4.9% 
(95%CI 3.1-6.7) in the celecoxib group and 6.4% (95%CI 4.3-8.4) in the diclofenac plus PPI 
group (Chan et al 2002). NSAID plus PPI therapy offers some gastroprotection, however, a 
COX-2 inhibitor plus PPI offers better protection.  One study compared celecoxib against 
celecoxib plus esomeprazole with the primary endpoint being recurrent ulcer bleeding (Chan 
et al 2007). Recurrent bleeding occurred in 8.9% in the celecoxib group and 0% in the 
combined group (P=0.0004). Unfortunately, there are no head-to-head trials comparing COX-
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2 plus PPI against NSAID plus PPI. If NSAIDS or COX-2 inhibitors are to be continued then 
a concomitant PPI should be given for the duration of treatment. In addition, H. Pylori should 
be tested for and treated to further reduce the risk of bleeding. 
• Anti-platelet agents. Antiplatelet therapy can cause AUGIB. Antiplatelet agents 
should be restarted as soon as the cardiovascular benefits outweigh the risk of further 
bleeding. The common dilemma is should antiplatelet therapy be discontinued, and for how 
long? Aspirin is often stopped, in up to 63% of patients in one study, in the context of 
AUGIB but is often not restarted prior to discharge (Cheung et al 2009). The cessation of 
anti-platelet therapy is associated with recurrent thrombotic events (Biondi-Zoccai et al 
2006). 
One prospective RCT examined patients taking aspirin who suffered AUGIB. Patients were 
assigned to aspirin or placebo immediately following endoscopic therapy plus high-dose 
intravenous PPI. Patients who received aspirin had lower all-cause mortality, 1.3% versus 
12.9% and lower mortality as a result of cardiovascular, cerebrovascular and gastrointestinal 
complications, 1.3% versus 10.3% (Sung et al 2010b). Recurrent ulcer bleeding was higher in 
the aspirin group, 10.3% versus 5.4% in the placebo group. As a result of this guidelines 
recommend the early re-introduction of antiplatelet therapy (Barkun et al 2010, NICE 2012). 
The recent European Society of Gastrointestinal Endoscopy (ESGE) suggest restarting aspirin 
immediately after endoscopy if low-risk stigmata is seen; in the context of high-risk stigmata 
the re-introduction of aspirin should be considered by day 3 provided that adequate 
haemostasis has been achieved (Gralnek et al 2015). However, this may seem counter-
intuitive when a patient has been admitted with bleeding, and so clinicians have been slow to 
change and adopt this guidance. 
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Aspirin plus a PPI is superior to clopidogrel alone in terms of the prevention of ulcer 
rebleeding (Chan et al 2005; Lai et al 2006). Rates of rebleeding in one study was 8.6% for 
clopidogrel compared with 0.7% for aspirin plus esomeprazole (Chan et al 2005). A second 
study found 0% ulcer complications in the aspirin plus esomeprazole group compared with 
13.6% in the clopidogrel alone group (Lai et al 2006). Pooled results of these two studies 
show a significant reduction in rebleeding with aspirin and a PPI versus clopidogrel (OR 
0.06, 95% CI 0.01-0.32), but no difference on mortality (OR 0.63, 95% CI 0.24-1.64) 
(Barkun et al 2010). With debate still raging of a significant interaction between clopidogrel 
and PPIs, it is felt that aspirin and a PPI is the best way forward in this situation (Disney et al 
2011). In patients receiving dual antiplatelet therapy concomitant PPI use is associated with 
lower rates of AUGIB (HR 0.13, 95% CI 0.03-0.56, P=0.001) (Bhatt et al 2010). 
Currently there is no evidence for the optimum management of patients on dual antiplatelet 
therapy (e.g. aspirin plus a thienopyridine) who develop AUGIB. Withholding antiplatelet 
therapy should be individualised based upon cardiovascular and gastrointestinal risk; for 
example, the indication for dual antiplatelet therapy, timing of stent placement, drug-eluting 
versus bare metal stent. However, it should be noted that PPI use in the context of dual 
antiplatelet therapy does reduce the incidence of AUGIB (Bhatt et al 2010; Kwok et al 2011; 
Lin et al 2011). PPI therapy confers better protection than H2RA (Lin et al 2011). 
In those patients remaining on aspirin it is important to recognise and eradicate H. Pylori. 
Among patients with H. pylori infection and a history of upper gastrointestinal bleeding who 
are taking low-dose aspirin, the eradication of H. pylori is equivalent to treatment with 
omeprazole in preventing recurrent bleeding (Chan et al 2001). 
The acute management of AUGIB in the context of ACS is dealt with elsewhere (section 
1.3.8).  
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1.2.10 Rebleeding 
Peptic ulcer bleeding 
Rebleeding had been thought to occur in approximately 20% (range 9-42%) of patients 
despite medical and endoscopic intervention (Schoenberg et al 2001).  However, a recent 
systematic review found lower rates of rebleeding of 13.9% (95% CI 8.4-19.4) (Lau et al 
2011). The most recent figures from the UK suggest a rebleeding rate of 13% (95% CI 12-14) 
(Hearnshaw et al 2011). 
In the event of rebleeding there are 4 options available: 
1. Medical management. The least effective option. Further fluid and RBC infusion in 
addition to intravenous PPI, but no further endoscopy. Only those patients deemed unfit 
for further intervention should be in this group. 
2. Re-endoscopy. A randomised trial comparing a second endoscopy with surgery reported 
favourable outcomes (Lau et al 1999). There were more complications in the patients 
assigned to surgery (OR 3.45, 95% CI 1.2-9.1). Endoscopic therapy reduced the need for 
surgery without an increase in mortality (Lau et al 1999). This is the preferred strategy in 
current international guidelines (Barkun et al 2010). 
3. Interventional radiology. This is fast becoming a more attractive alternative to surgery 
for patients deemed high-risk when endoscopic therapy has failed (Loffroy et al 2010). 
Selective angiography and embolisation of a culprit vessel can be performed under light 
sedation in those patients in whom surgery is not a viable option due to co-morbidity. 
The need for surgery varies between 2-37% and 30-day mortality rates between 4-46% 
(Loffroy et al 2010). When compared with surgery for those patients who failed 
endoscopic therapy several retrospective studies found transarterial embolisation reduced 
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the need for surgery without increasing mortality (Ripoll et al 2004; Wong et al 2011). 
This is despite the embolisation group being older and with more cardiac co-morbidities. 
More complications were seen in the surgical group (Wong et al 2011). Figures from the 
UK national gastrointestinal bleed audit reveal that 1.2% of patients underwent an 
interventional radiological procedure (Hearnshaw et al 2011). 
4. Surgery. The need for surgery has been greatly reduced by the widespread use, and 
increasing complexities, and efficacy of therapeutic endoscopic and interventional 
radiology. Surgery should be reserved for those patients who have failed endoscopic and 
interventional radiology (Schoenberg et al 2001). The results from the latest UK 
gastrointestinal bleed audit reveal that 1.9% of patients underwent surgical intervention 
(Hearnshaw et al 2011). 
 
1.2.11 Acute upper gastrointestinal bleeding and cardiovascular disease 
Death following AUGIB is often due to co-morbid disease, rather than bleeding itself, in up 
to 80% of cases (Sung et al 2010a). Several studies show that death following AUGIB is 
often due to cardiovascular disease.  
Up to 32% of patients in a study of peptic ulcer bleeding died from either cerebrovascular 
disease or myocardial infarction (Smart and Langman 1986). One study of survival of 
patients suffering from peptic ulcer disease followed patients for a median of 36 months. Of 
the 121 patients who were followed up 30 (25%) died during the study period. Of these, 66% 
(n=20) died from cardiovascular disease; 23% (n=7) from myocardial infarction and 20% 
(n=6) from a stroke (Kubba et al 1997). Similar associations between peptic ulcer disease and 
subsequent mortality from cardiovascular disease have also been reported in the UK 
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population (Hudson et al 1995). Analysis of the General Practice Research Database found 
that of 978 patients presenting with peptic ulcer bleeding cardiovascular disease was the 
leading cause of death; 30.3%, RR 1.7 (95% CI 1.2-2.5) with cerebrovascular disease 
accounting for a further 6.5% of deaths (Ruigómez et al 2000).  
The largest study (> 10000 patients) of outcomes from peptic ulcer bleeding found that 
cardiovascular disease was responsible for 19% of all deaths; ACS and heart failure 13.5% 
and cerebrovascular disease 5.4% (Sung et al 2010a). A study by the same group found that 
the early resumption of low-dose aspirin (used for secondary prevention), rather than 
withholding for 8 weeks, following peptic ulcer bleeding resulted in lower cardiovascular 
events (Sung et al 2010b). Another study found a strong association between the 
discontinuation of aspirin following a peptic ulcer bleed and the risk of death and acute 
cardiovascular events during the first six months following admission with bleeding (Derogar 
et al 2013). In this study aspirin was discontinued in 40% of patients with peptic ulcer 
bleeding. Those patients with cardiovascular co-morbidities who discontinued aspirin had a 
7-fold increase (HR 6.9, 95% CI 1.4-34.8) in the risk of death or acute cardiovascular events 
within the first 6 months.  
To conclude there appears to be sufficient evidence to show an association between non-
variceal AUGIB and mortality related to cardiovascular disease. 
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1.3 Bleeding in acute coronary syndromes 
1.3.1 Introduction to bleeding in acute coronary syndromes 
Cardiovascular disease is the leading cause of death in industrialised countries, with coronary 
artery disease (CAD) the most prevalent manifestation (McAloon et al 2016). The 
presentation of CAD varies from silent ischaemia through to stable angina, unstable angina, 
myocardial infarction, heart failure and sudden death (Hamm et al 2011). 
The acute coronary syndromes encompass a spectrum of unstable coronary artery disease 
including unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) 
and ST segment elevation myocardial infarction (STEMI). It is diagnosed based upon the 
specific characteristics of each element of the triad of: clinical presentation (including a 
history of coronary artery disease), electrocardiographic changes (such as ST segment 
elevation) and biochemical cardiac markers (such as an elevated troponin level) (SIGN 
2013). 
The initial management of ACS involves patient stabilisation and pain relief. The continuing 
management depends upon the presentation. A patient with a STEMI invariably undergoes 
coronary angiography and primary percutaneous coronary intervention with subsequent 
antiplatelet and antithrombotic medications. However, patients with UA and NSTEMI are 
typically initially treated with antiplatelet and antithrombotic medications with subsequent 
coronary angiography with, or without, primary percutaneous coronary intervention (Hamm 
et al 2011; Steg et al 2012). 
There are numerous pharmacological interventions used in the management of ACS such as 
anti-platelet agents (e.g. aspirin, thienopyridines/P2Y12 inhibitors, glycoprotein IIb/IIIa 
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inhibitors) and anti-thrombotic agents (e.g. heparin, direct thrombin inhibitors). These 
medications are regularly used in combination.  
The advent of potent anti-platelet and anti-thrombotic agents over the past decade has 
resulted in significant improvement in reducing ischaemic events in ACS, which has resulted 
in a reduction in the risk of death (Pham et al 2011). Bleeding was once regarded as merely a 
reversible side effect of treatment to Cardiologists; themselves favouring the use of 
treatments aimed at reducing recurrent ischaemia and the risk of death (Armstrong et al 
1998). However, times have changed and bleeding has now been established as not just a side 
effect easily rectified by stopping treatment, but as an independent risk for poor short- and 
long-term outcomes in the context of ACS. Bleeding is the most frequent non-ischaemic 
complication observed in the management of ACS. In fact bleeding is an area of much 
interest and is now covered in detail in international guidelines for the treatment of ACS 
(Hamm et al 2011). 
 
1.3.2 Epidemiology and aetiology of bleeding in acute coronary syndromes 
Historically, trials examining the treatment of ACS with antithrombotic agents have reported 
major bleeding rates between 0.4% - 10.6% (GUSTO IIb 1996, PRISM 1998, PURSUIT 
1998, PARAGON-B 2002). The incidence of bleeding is likely to be higher outside 
randomised controlled trials in the ‘real-life’ population as high-risk patients are often 
excluded in therapeutic trials. The incidence of major bleeding from registry data is as high as 
11.5% with overall bleeding rates between 5.2 - 36% (Sobieraj-Teague et al 2008). 
Interestingly, despite the use of more aggressive antithrombotic treatment regimens, data 
from the Global Registry of Acute Coronary Events (GRACE) registry from 2000-2007 
suggests that the incidence of major bleeding has decreased over time from 2.6% to 1.8% 
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(Fox et al 2010). This may indicate that clinicians are now more aware of bleeding 
complications and as a result have adapted management strategies accordingly (Hamm et al 
2011). 
The first large observational study to identify risk factors for bleeding in ACS was published 
in 2003 (Moscucci et al 2003). This study analysed data from 24045 patients from the 
GRACE registry; the incidence of bleeding was 3.9%. Older age, female gender, histories of 
bleeding and chronic kidney disease were all independently associated with major bleeding. 
Interventions associated with bleeding were percutaneous coronary intervention (PCI), GP 
IIb/IIIa receptor blockers and pulmonary artery catheters (Moscucci et al 2003). 
The first authors to associate bleeding with poor outcomes in the context of ACS found that 
mild bleeding occurred in 16.6%, moderate in 9.8% and severe in 1.2% of patients (Rao et al 
2005). This study examined 26452 patients with ACS from 4 clinical trials (GUSTO IIb, 
PURSUIT and PARAGON A and B). The Global Utilisation of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding was 
used. Risk factors for bleeding were old age, reduced body weight, female gender and the 
presence of cardiac risk factors such as diabetes, hypertension.  
Numerous studies have evaluated risk factors for major bleeding (Eikelboom et al 2006; 
Khan et al 2015; Kinnaird et al 2003; Manoukian et al 2007; Mehran et al 2009a; Moscucci 
et al 2003; Rao et al 2005; Spencer et al 2007). Risk factors for bleeding can be classified 
into patient characteristics and therapeutic.  
More recently there has been interest in biomarkers associated with bleeding events and one 
recent study found that higher levels of growth differentiation factor-15 (GDF-15) is 
associated with risk of bleeding (Hagström et al 2016). Patients with higher levels of the 
renal function biomarkers, beta-trace protein and cystatin C, are at increased risk of major 
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bleeding (López-Cuenca et al 2013). Point of care platelet function testing has also been 
studied; those patients with low on-treatment platelet reactivity had a higher risk of bleeding 
(Cuisset et al 2013; Holm et al 2014; Huczek et al 2013; Patti et al 2011). Although of 
academic interest, the use of platelet function testing has yet to become routine clinical 
practice (Aradi et al 2015).  
A summary of risk factors for bleeding in ACS can be seen in table 1.6 and figure 1.2. 
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Table 1.6 Risk factors for bleeding in acute coronary syndromes 
Patient characteristics Treatment related risk factors 
Older age GP IIb/IIIa inhibitors 
Female gender Unfractionated heparin 
Lower body mass index Thienopyridines 
Comorbidity: chronic kidney disease, 
hypertension, diabetes, previous stroke 
Diuretics 
Lower blood pressure and higher pulse on 
admission 
Inotropes 
Smoking Invasive therapy e.g. PCI, coronary artery 
bypass graft (CABG), intra-aortic balloon 
pump (IABP) 
Prior history of bleeding  
ST-segment deviation  
Baseline anaemia  
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Figure 1.2 Risk factors for bleeding in ACS. An outline of the risk factors that are non-
modifiable, such as patient characteristics, with those that can be modified such as treatments 
chosen and procedure characteristics (adapted from Pham et al 2011). 
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1.3.3 Site of bleeding 
The most common sites for bleeding complications are, in descending order (Moscucci et al 
2003, Spencer et al 2007): 
• Gastrointestinal bleeding   31.5% 
• Vascular access site   23.8 – 29% 
• Retroperitoneal  6.0% 
• Genitourinary   4.8% 
• Intracerebral   6% 
In patients undergoing PCI the most common site of bleeding is the vascular access site. The 
site of access for PCI is important. Femoral arterial site complications (e.g. haematoma and 
pseudo-aneurysm) are responsible for a significant portion of the bleeding complications 
occurring during treatment for ACS (Doyle et al 2008; Moscucci et al 2003; Segev et al 
2005). Several studies show that a trans-radial approach (i.e. an arterial puncture at the wrist 
as opposed to the groin which is used with the femoral approach) results in a lower incidence 
of bleeding events, with major bleeding events reduced by 73% in one study when the trans-
radial approach was used (Agostini et al 2004; Jolly et al 2009). In addition a trans-radial 
approach, as compared to femoral, has been shown to reduce mortality and major adverse 
cardiovascular events (Andò and Capodanno 2015; Karrowni et al 2013).  
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1.3.4 Definition of bleeding in acute coronary syndromes 
The wide range of definitions used when assessing various anti-platelet or anti-thrombotic 
agents causes confusion with interpretation of the rate of bleeding and in the association of 
bleeding with poor outcomes. Lack of standardisation makes it difficult to optimally organise 
key clinical trial processes such as adjudication, and even more difficult to interpret relative 
safety comparisons of different antithrombotic agents across studies, or even within a given 
trial, because results may vary according to the definition(s) used for bleeding (Mehran et al 
2011a). 
The Thrombolysis in Myocardial Infarction (TIMI) and Global Use of Strategies to Open 
Occluded coronary arteries (GUSTO) definitions of major bleeding were first developed in 
the thrombolytic era to assess the short-term bleeding associated with thrombolytic agents in 
the treatment of patients with a STEMI. As a result of these classifications being historic and 
orientated towards thrombolytic treatment they may underestimate episodes of bleeding in 
current clinical trials (Pham et al 2011). In addition, the TIMI definition for bleeding has 
evolved over time, the current definition being shown in table 1.7 (Mehran et al 2011a). 
Notably, the GUSTO criteria for bleeding is unique from other definitions in that it does not 
require changes in haemoglobin, nor does it quantify the amount of blood transfused (Mehran 
et al 2011a). More recent definitions of bleeding (e.g. CURE, OASIS, ACUITY) have tried 
to overcome the shortcomings of TIMI and GUSTO by combining both laboratory and 
clinical parameters. 
The definition used for bleeding has an effect on the clinical impact of bleeding found in 
clinical trials. For example, one observation from pooled analysis of the GUSTO trial found 
that there was a stepwise increase in the adjusted hazard of 30-day death or MI with 
worsening GUSTO bleeding (HR [95% CI], GUSTO mild 1.20 [1.05 to 1.37]; moderate 3.28 
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[2.88 to 3.73]; severe 5.57 [4.33 to 7.17]), whereas increased risk but no stepwise progression 
was observed with all three levels of TIMI bleeding (TIMI minimal 1.84 [1.63 to 2.08]; TIMI 
minor 1.64 [1.31 to 2.04]; major 1.45 [1.23 to 1.70]). When both bleeding scales were 
included in the same model, the risk with GUSTO bleeding persisted; however, the 
association between TIMI bleeding and outcome was no longer significant (Rao et al 2006). 
This suggested that clinically significant bleeding added prognostic value to laboratory 
markers. In another study of patients undergoing PCI, the GUSTO, ACUITY and TIMI 
classifications identified bleeding rates of 2.3%, 1.9% and 2.1% respectively; the GUSTO 
criteria identified all bleeding events but there were 22 (18.6%) and 8 (6.8%) that did not 
meet ACUITY and TIMI criteria respectively (Fleming et al 2011).  
The various definitions used in therapeutic trails can be seen in table 1.7. 
Due to the problems with definitions of bleeding, the International Society on Thrombosis 
and Haemostasis (ISTH) criteria defined universal criteria for bleeding (Schulman et al 
2005). That is: 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in haemoglobin level of 2 g/dL or more, or leading to 
transfusion of two or more units of whole blood or red cells. 
 
The ISTH criteria were therefore the criteria adopted for the purpose of the study. At the time 
of study conception the standardised Bleeding Academic Research Consortium (BARC) 
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definition of bleeding for cardiovascular clinic trials had not yet been published and as a 
result were not considered in the design of this study (Mehran et al 2011a). 
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Table 1.7 Definitions of major bleeding used in cardiovascular trials 
Studies TIMI 1987 GUSTO 1993 GRACE 2003 ACUITY 2006 REPLACE-2 
2007 
HORIZONS-
AMI 2008 
OASIS-5 
2009 
Clinical Intracranial 
bleed 
Intracranial 
bleed 
Death Intracranial, or 
intraocular bleed 
Intracranial, 
intraocular or 
retroperitoneal 
bleed 
Intracranial, 
intraocular bleed 
Clinically 
overt fatal 
bleed 
Haemodynamic 
compromise 
requiring 
intervention 
Haemorrhagic 
SDH 
Access site 
bleeding requiring 
intervention 
Access site 
haematoma > 5cm 
or requiring 
intervention 
Symptomatic 
intracranial, 
retroperitonea
l or 
intraocular 
bleeding 
leading to 
significant 
visual loss 
 Stroke Haemotoma > 5cm Reoperation for 
bleeding 
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  Reoperation for 
bleeding 
  
Transfusion 
requirement 
  ≥ 2 units RBC  ≥ 2 units RBC Blood product 
transfusion 
≥ 2 units 
RBC 
Laboratory 
parameters 
↓ Hb > 5g/dL 
or ↓ Hct > 
15% 
 Absolute ↓ Hct 
≥ 10% 
↓ Hb ≥ 4g/dL 
without overt 
bleeding source or 
↓ Hb ≥ 3g/dL with 
source 
Any ↓ Hb ≥ 
4g/dL 
↓ Hb ≥ 3g/dL 
with overt 
bleeding 
↓ Hb ≥ 4g/dL 
without overt 
bleeding source or 
↓ Hb ≥ 3g/dL 
with source 
↓ Hb ≥ 3g/dL 
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1.3.5 Prognosis and implications following a bleeding event 
Once thought of as an inevitable side effect of the treatment for ACS, bleeding is now 
widely recognised as an independent risk factor for further morbidity and mortality. 
Major bleeding was first recognised to be associated with an increased risk of hospital 
death in 2003 with an adjusted OR 1.64 (95% CI 1.18-2.28) (Moscucci et al 2003). 
Bleeding is also associated with an increased risk of further ischaemic events (Rao et 
al 2005). 
Rao and colleagues were amongst the first to associate major bleeding with both 
short- and long-term adverse outcomes (Rao et al 2005). In this analysis of 26452 
patients (using the GUSTO definition of bleeding) 27.6% of patients had ≥ 1 bleeding 
event (mild, moderate or severe).  Severity of bleeding was associated with a step-
wise increase in adverse outcomes (see table 1.8). Those with severe bleeding had an 
in-hospital mortality of 25.7% compared with 2.9% in those without bleeding. 
Patients were also noted to have had an increase in recurrent ischaemic events. 
In the short term, analysis from the GRACE registry of 40000 patients with ACS 
found that those patients, who suffered major bleeding, were 4 times more likely to 
die during the admission than those without bleeding (20.9% versus 5.6%; P<0.001) 
(Spencer et al 2007). Similarly, those who survived major bleeding in hospital were 
more likely to die during post-discharge follow up than those who did not (7.9% 
versus 5.2%, P=0.002).  
Similar results were found by Eikelboom who analysed data from OASIS-1, OASIS-2 
and CURE (34146 patients with ACS). Major bleeding was associated with higher 
rates of 30-day mortality (12.8% versus 2.5%, P<0.0001) (Eikelboom et al 2006).  
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Bleeding is not only a short-term problem (i.e. related to in hospital death) but also 
translates into a poorer prognosis in the longer term. The ACUITY investigators 
found that bleeding was not only an independent predictor of 30-day mortality but 
that this phenomenon was still present at 1 year (Manoukian et al 2007; Mehran et al 
2009). This 1-year association of bleeding with increased risk of mortality is further 
demonstrated with the pooled analysis of the REPLACE-2, ACUITY and 
HORIZONS-AMI trials; major bleeding was associated with a HR 4.89 (95% CI 
3.61-6.63) for mortality at 1 year (Mehran et al 2011b).  Analysis from the 
CRUSADE registry took things one step further. The authors found that major 
bleeding continued to be significantly associated with higher mortality for 3 years; 31 
days to 1 year (HR 1.19, 95% CI 1.10-1.29), 1 year to 3 years (HR 1.09, 95% CI 1.01-
1.18) (Lopes et al 2012). 
Further studies examining the association between major bleeding and adverse events 
are summarised in table 1.9. 
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Table 1.8 Severity of bleeding and adverse events (Adapted from Rao et al 2005) 
 
Outcome Degree of bleeding 
  None Mild Moderate Severe 
Unadjusted rates 
(%) 
    
30-d end points     
Death 549/19110 
(2.9%) 
155/4387 
(3.5%) 
154/2499 
(5.9%) 
79/307 
(25.7%) 
MI 1412/19110 
(7.4%) 
501/4373 
(11.5%) 
605/2591 
(23.4%) 
100/306 
(32.7%) 
Death or MI 1758/19110 
(9.3%) 
572/4372 
(13.1%) 
675/2591 
(26.1%) 
151/306 
(49.4%) 
6-m end points     
Death 983/18886 
(5.2%) 
273/4358 
(6.3%) 
253/2566 
(9.9%) 
107/305 
(35.1%) 
     
Adjusted HR 
(95%CI) 
    
30-d end points     
Death 1 1.6 (1.3-1.9) 2.7 (2.3-3.4) 10.6 (8.3-
13.6) 
Death or MI 1 1.3 (1.2-1.5) 3.3 (2.9-3.7) 5.6 (4.6-6.8) 
6-m end point     
Death 1 1.4 (1.2-1.6) 2.1 (1.8-2.4) 7.5 (6.1-9.3) 
30-d = 30 day, 6-m = 6 months 
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Table 1.9 Studies examining bleeding and adverse outcomes (adapted from Pham et al 2011) 
Trials/study design Bleeding definition Outcomes Reference 
Meta-analysis (GUSTO IIb, PURSUIT, GUSTO criteria 30-d hazard of death by bleeding severity Rao et al 2005 
 PARAGON A & B)  Mild: HR 1.6 (1.3-1.9)  
  Moderate: HR 2.7 (2.3-3.4)  
  Severe: HR 10.6 (8.3-13.6)  
  6-m mortality  
  Mild: HR 1.4 (1.2-1.6)  
  Moderate: HR 201 (1.8-2.4)  
  Severe: HR 7.5 (6.1-9.3)  
    
OASIS-1, OASIS-2, CURE 
Transfusion ≥2 units 
RBC,  30-d hazard of death Eikelboom et al 2006 
 or life threatening HR 5.37; P<0.0001  
  Between 30-d - 6-m  
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  HR 1.54; P=0.047  
    
OASIS-5 * 
30-d & 180-d composite endpoints ↑4-fold in those 
with bleeding Budaj et al 2009 
    
GRACE registry GRACE criteria 
In-hospital death higher with bleeding (HR 1.9, 
95% CI 1.6-2.2) Spencer et al 2007 
    
Phase III ACUITY ACUITY criteria 
30-d mortality, composite ischaemia, and stent 
thrombosis  Manoukian et al 2007 
  higher with bleeding (P<0.0001)  
    
ACUITY ACUITY criteria 
1-year mortality: ↑3.5 times in those with major 
bleeding Mehran et al 2009 
    
REPLACE-2 * 30-d mortality ↑ in patients with bleeding (5.1% vs. Feit et al 2007  
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0.2%; P<0.001) 
  
6-m mortality ↑ in patients with bleeding (6.7% vs. 
1.0%; P<0.001)  
  
1-year mortality ↑ in patients with bleeding (8.7% 
vs. 1.9%; P<0.001)  
    
Retrospective analysis of >10000 patients  TIMI criteria Major bleeding independent risk factor of  Kinnaird et al 2003 
undergoing PCI  in-hospital mortality (OR 3.5; P=0.0001)  
    
Meta-analysis (ISAR-REACT, -SWEET, -SMART-
2, REACT-2) TIMI criteria 
Bleeding independent risk factor for mortality (HR 
2.96; P<0.001) Ndrepepa et al 2008 
*= Major bleeding: clinically overt fatal bleeding, symptomatic intracranial, retroperitoneal, intraocular bleed, transfusion ≥2 units RBC, ↓Hb ≥3g/dL 
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1.3.6 Management of bleeding complications 
The prevention of bleeding is as important as the treatment of the bleeding 
complication itself. As AUGIB accounts for a large proportion of bleeding 
complications the use of PPIs have been recommended to protect against bleeding 
(Bhatt et al 2008). PPIs have been found to reduce the frequency of overt AUGIB 
when prescribed with clopidogrel – HR 0.13 (95% CI 0.03-0.56) (Ng et al 2008, Bhatt 
et al 2010). Other preventative strategies include the use of radial over femoral access 
(Jolly et al 2009), and the correct choice and dosage of medications depending on the 
patients bleeding risk (Alexander et al 2010). 
The treatment of bleeding largely depends upon the site and severity of bleeding. In 
general terms, treatment is supportive. Minor bleeding can be managed conservatively 
without the interruption of antiplatelet and antithrombotic therapy, however, in major 
bleeding, cessation and reversal of antiplatelet and antithrombotic therapy may be 
required. The risk of interrupting antiplatelet therapy should be weighed against the 
risk of a recurrent thrombotic event especially stent thrombosis following PCI. 
Treatment should be restarted once haemorrhage has been controlled for at least 24 
hours (Hamm et al 2011).  
Blood products may be required to correct abnormalities in haemostasis, haemoglobin 
and platelet count (e.g. fresh frozen plasma, platelet transfusion, red blood cell 
transfusion). These abnormalities may be the due to either the bleeding itself or as a 
side effect of drug treatment (e.g. heparin, GP IIb/IIIa inhibitors). It should be noted 
however, that blood transfusion itself is associated with poor outcomes in the context 
of ACS (Alexander et al 2008; Jolicoeur et al 2009; Rao et al 2004; Shishebor et al 
2009). Transfusion has also been shown to have adverse effects on mortality in 
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critically ill patients; in a study of restrictive versus liberal blood transfusion strategies 
those in the restrictive strategy group had a lower mortality (Hébert et al 1999; 
Villanueva et al 2013). 
 
1.3.7 Explanation for poor outcomes 
The mechanism by which an episode of bleeding leads to poor outcomes (recurrent 
ischaemic events and death) is at present poorly understood although several 
mechanisms have been suggested.  
One explanation is the need to discontinue antiplatelet and antithrombotic medications 
when bleeding occurs. This, however, leads to an increased risk of recurrent 
thrombotic events, particularly stent thrombosis after PCI (Hamm et al 2011). 
Other potential mechanisms by which bleeding leads to poor outcomes include 
(Disney et al 2011; Eikelboom et al 2006; Fitchett 2007; Manoukian et al 2007; 
Mehran et al 2009a; Spencer et al 2007): 
• Adverse effects of hypotension on end organs 
• Platelet and coagulation activation associated with anaemia 
• Adverse effects of blood transfusion 
• Interventions required to control bleeding (e.g. surgery) 
• Bleeding may unmask a covert diagnosis with a poor prognosis (e.g. 
malignancy) 
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1.3.8 Gastrointestinal bleeding in the context of acute coronary syndromes 
Gastrointestinal bleeding is the most common site of bleeding in patients treated with 
ACS. In patients who present with AUGIB in the setting of ACS, the bleed may have 
precipitated the ACS or occurred as a consequence of anti-platelet and other 
anticoagulants given during ACS (Lin et al 2006).  
AUGIB complicates approximately 0.7-3% of patients following ACS (Abbas et al 
2005; Chin et al 2007; Lin et al 2006; Moukarbel et al 2009; Nikolsky et al 2009). 
Bleeding occurs at a mean time of 2.8 days in one study (Chin et al 2007). 
The risk of AUGIB in this patient group is commonly due to the use of anti-platelet 
therapy. Anti-platelet agents are important for 2 reasons; firstly, they reduce recurrent 
ischaemic events, and secondly, they prevent the risk of stent thrombosis. Late stent 
thrombosis, a phenomenon related to drug eluting stents, means prolonged use of dual 
anti-platelet therapy is needed. Currently, patients with a stent in situ require a 
minimum of 4 weeks (bare metal stents) and 12 months (drug eluting stents) of anti-
platelet therapy (Grines et al 2007). Following this period, patients continue treatment 
with aspirin monotherapy. 
Non-compliance or withdrawal of aspirin increases the risk of recurrent 
cardiovascular events. Aspirin non-adherence or withdrawal is associated with three-
fold higher risk of major adverse cardiac events (OR=3.14 [95% CI 1.75-5.61], 
P=0.0001). This risk was magnified in patients with intracoronary stents, as 
discontinuation of antiplatelet treatment was associated with an even higher risk of 
adverse events (OR=89.78 [29.90-269.60]) (Biondi-Zoccai et al 2006). 
• Aspirin. The risk of AUGIB with aspirin is dose related (Weil et al 1995). 
The 75 mg dose, that is commonly used for the secondary prevention of 
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cardiovascular events, carries an OR of 2.3 (95% CI 1.2-4.4) for AUGIB. A 
more recent study found that aspirin alone had an OR 1.8 (95% CI 1.5-2.1) 
(Hallas et al 2006). 
• Clopidogrel. The OR for AUGIB for patients taking clopidogrel alone is 1.9 
(95% CI 0.6-2.1) (Hallas et al 2006).  
• Dual antiplatelet therapy. Patients taking both aspirin and clopidogrel have 
an OR of 7.4 (95% CI 3.5-15) and a HR 3.18 (95% CI 1.91-5.29) for the 
development of AUGIB (Hallas et al 2006; Moukarbel et al 2009). 
• Warfarin. Patients on warfarin have an 8 fold increased risk of AUGIB 
compared with controls (OR 7.8, 95% CI 2.8-21.5) (Weil et al 2000). 
The suggested treatment of patients with AUGIB in the context of recent coronary 
stent insertion is shown in figure 1.3.  
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Figure 1.3 Suggested management algorithm for the management of acute upper 
gastrointestinal bleeding after recent stent implantation (Tan et al 2009).  
aSystolic blood pressure > 100mmHg, pulse > 100 beats per minute.  
bFactors associated with a high risk of stent thrombosis: impaired LV systolic 
function, diabetes mellitus, renal failure, long segment of stent (>20mm) and recent 
coronary intervention (within 3 months of BMS, within 12 months of DES). 
cFactors associated with increased risk of continued bleeding: endoscopic diagnosis 
(visible vessel and stigmata of recent haemorrhage).   
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1.3.8.1 Outcomes following acute upper gastrointestinal bleeding in acute 
coronary syndromes 
Short term 
Haematological indices are affected in those patients with GI bleeding. In particular, 
patients with GI bleeding have a higher incidence of acquired thrombocytopenia 
(21.6% vs. 10.5%, p < 0.001) and haemoglobin drop of ≥ 3g/dL (30.4% vs. 1.3%) 
(Nikolsky et al 2009). High-risk lesions on endoscopy were identified in 33% of 
patients and rebleeding occurred in 4.5% of patients (Chin et al 2007). 
Bleeding has a profound effect on outcomes. Length of hospital stay is increased from 
a median of 3 to 6 days in patients with gastrointestinal bleeding (Abbas et al 2005; 
Nikolsky et al 2009). In-hospital mortality is higher in patients suffering from an 
AUGIB; 10% versus 2.8% in patients not suffering from bleeding (Abbas et al 2005). 
In one case-control study 30-day mortality was 11.9% in patients with GI bleeding, 
compared to 0.5% for controls (Chin et al 2007). Further evidence suggests GI 
bleeding is an independent predictor of all-cause mortality (HR 4.87, IQR 2.61-9.08), 
cardiac mortality (HR 5.35, IQR 2.71-10.59) and composite ischaemia (HR 1.94, IQR 
1.14-3.30) (Nikolsky et al 2009) – see figure 1.4. 
 
Long term 
In addition to an increase in short term mortality, evidence supports GI bleeding as a 
predictor of mortality at 1 year (Nikolsky et al 2009). It should be noted that the 
majority of patients with AUGIB did not meet the criteria for major bleeding.  
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In the valsartan in acute myocardial infarction trial (VALIANT) analysis 35.7% 
(n=35) died during follow up (median follow-up was 24.7 months). GI bleeding was 
associated with an increased risk of all-cause death, with a HR of 3.57 (95% CI 2.56-
5.00), even after adjustment for important confounding factors. It should be noted that 
the majority of deaths in this study were from cardiovascular causes (60%) rather than 
the bleeding itself (11.4%) (Moukarbel et al 2009). 
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Figure 1.4 Ischaemic events and mortality at 30 days and 1 year in patients with 
ACS, with and without gastrointestinal bleeding. A = 30 day, B = 1 year, GIB = 
gastrointestinal bleeding. This figure demonstrates that patients who suffer from 
AUGIB in the context of ACS have a higher incidence of recurrent cardiac events and 
mortality; both in the short term and long term (Nikolsky et al 2009).  
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1.3.9  Use of proton pump inhibitors for the prevention of acute upper 
gastrointestinal bleeding in acute coronary syndromes 
Proton pump inhibitor use reduces the risk of GI bleeding associated with aspirin use 
(Chan et al 2005, Bhatt et al 2010). 
The use of proton pump inhibitors after PCI is associated with a reduction in the rate 
of GI bleeding (Chin et al 2007). Logistical regression analysis found that PPI therapy 
was associated with reduced rates of upper GI bleeding (OR 0.08, 95% CI 0.02-0.40 
(Chin et al 2007). Other studies have found PPIs to reduce the risk of AUGIB; HR 
0.13 (95% CI 0.03-0.56) (Bhatt et al 2010), RR 0.17 (95% CI 0.04-0.76) (Lin et al 
2011), RR 0.04 (95% CI 0.002-0.21) (Ng et al 2008). 
 
1.3.9.1 The interaction between clopidogrel and proton pump inhibitors 
There has been much controversy over the use of PPIs as gastroprotection in patients 
on dual antiplatelet therapy, particularly clopidogrel.  
Concerns were initially raised of an interaction between clopidogrel and PPIs in 2008 
(Gilard et al 2008). A study from 2006 found clopidogrels antiplatelet activity was 
diminished in patients receiving PPI treatment (Gilard et al 2006). Several 
retrospective studies further suggested a link between co-prescription of a PPI and 
clopidogrel, and an increased risk of adverse clinical outcomes (Dunn et al 2008; Ho 
et al 2009; Juurlink et al 2009; Pezalla et al 2008). However, as with any 
retrospective analysis the influence of compounding factors is problematic and may 
lead to inaccurate results and conclusions.  
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Several studies have found no clinically significant interaction including the only 
prospectively designed randomised controlled trial (Bhatt et al 2010; O’Donoghue et 
al 2009; Rassen et al 2009). 
Current thinking is that PPIs offer clear protection against AUGIB in patients on dual 
antiplatelet therapy and the concern over clinically relevant interactions with 
clopidogrel, although biologically plausible, is not yet proven (Disney et al 2011). 
In summary, the evidence suggests that a bleeding event in ACS increases risk of 
subsequent cardiovascular events and mortality in both the short and long term; a 
phenomenon that has yet to fully explained. 
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1.4 Platelets and Platelet activation 
1.4.1 Platelet structure and function 
Platelets are small fragments of megakaryocyte cytoplasm with an average volume of 
7-8 fL. When studied with electron microscopes non-activated platelets are shaped 
like biconvex discs, have a convoluted surface and contain mitochondria, granules, 
two systems of cytoplasmic membranes, microfilaments, microtubules and many 
glycogen molecules. When platelets change their shape during activation, the 
microtubules break their connections with the cell membrane and contract inwards 
(Wickramasinghe et al 2011). 
There are 4 types of platelets granules: 
1. Dense bodies (δ granules) – these contain ADP, ATP, calcium, adrenaline and 
serotonin – involved in platelet aggregation. 
2. α granules – contain platelet factor 4, β-thromboglobulin, fibrinogen, 
fibronectin. 
3. Lysosomal (λ) granules – contain acid phosphatase, cathepsin, β-
glucuronidase, and β-galactosidase. 
4. Peroxisomes – contains catalase. 
The normal range for platelet count in peripheral blood is between 150-450 x 109/L. 
The life span of normal platelets is 8-10 days (Wickramasinghe et al 2011). 
Platelets release an array of agonists, such as ADP; adhesive molecules, such as P-
selectin, thrombospondin, fibrinogen and vWF; coagulation factors; and growth 
factors (Jennings 2009). 
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The main function of platelets is their role in haemostasis with the formation of a 
haemostatic plug/thrombus in response to endothelial damage (Thachil 2015). Under 
physiological conditions platelets do not interact with the vessel wall (Gawaz et al 
1999). However, when endothelial cells of vessel walls are damaged and shed, 
platelets adhere to subendothelial connective tissue via vWF attached to a specific 
receptor on the platelet membrane, glycoprotein Ib-IX. This leads to activation of the 
platelet and the release of the contents from platelet granules; initially from the dense 
granules followed by α granules. The ADP released from the dense bodies causes an 
interaction between platelets, leading to aggregation. Aggregation is preceded by an 
alteration of the cell membrane, leading to a calcium-dependent binding of fibrinogen 
to platelet receptors on the membrane glycoprotein IIb-IIIa. The process of 
aggregation continues until a platelet plug occludes the damaged vessel 
(Wickramasinghe et al 2011).   
Platelet activation by agonists results in rapid changes in platelet morphology, platelet 
aggregation, granule secretion and involvement of the cell surface in coagulation 
reactions (Jennings 2009). Activated platelets release contents from storage granules 
and generate thromboxane A2 which is a potent vasoconstrictor and platelet agonist 
leading to further platelet activation (Reilly and Fitzgerald 1993).   
The process of platelet activation is a receptor-mediated response of resting platelets 
to a variety of specific stimuli originating either from activated proteins of the 
coagulation cascade (e.g. thrombin), subendothelial matrix proteins (e.g. collagen), or 
specific mediators such as ADP and adrenaline. The receptor mediated signals leads 
to ion fluxes, phosphoinositol breakdown and protein phosphorylation which regulate 
the reorganisation of the cytoskeleton, shape change, glycoprotein redistribution, 
expression of procoagulant surface and the release reaction. Furthermore, inside-out 
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signalling transform GPIIb/IIIa complex to a conformational state that is competent 
for binding of ligands such as fibrinogen or vWF. This process is the prerequisite for 
platelet aggregation and for thrombus formation on subendothelial matrices (Schmitz 
et al 1998). The changes that occur upon platelet activation are summarised in figure 
1.5. 
In addition to their haemostatic role, platelets are protagonists of inflammation and 
are activated in inflammation (Gawaz et al 2005; Ripoche et al 2011). Platelet 
adhesion to monocytes is mediated by the platelet surface expression of P-selectin. As 
platelets are involved in both inflammation and thrombosis the formation of 
monocyte-platelet aggregates may represent targeting of both cell types to specific 
inflammatory or thrombotic sites (Furman et al 2001). 
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Figure 1.5 The changes that occur during 
platelet activation.  
These are also the targets for direct and indirect 
methods to measure platelet activation (Tan and 
Lip 2005). 
Activated 
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1.4.2 Platelets in upper gastrointestinal bleeding 
Very little is known about the role of platelets with respect to AUGIB. In particular 
there is no study that looks at platelet activation or function in the context of AUGIB, 
however, it is well known that anti-platelet agents are associated with AUGIB and as 
a result, the role of platelets in AUGIB is a vitally important, yet unexplored area 
(Hallas et al 2006).  
The role of platelets in AUGIB is of particular interest given the results from a recent 
study (Sung et al 2010a). This study group investigated 156 patients presenting with 
AUGIB with a history of aspirin use as secondary prophylaxis for cardiovascular 
diseases. Following endoscopic therapy for peptic ulcer bleeding, patients were 
randomised to either restart low-dose aspirin immediately or placebo for 8 weeks. 
During follow up recurrent ulcer bleeding occurred in 10.5% in the aspirin group and 
5.4% in the placebo group (difference 4.9%, 95% CI -3.6-13.4). Patients receiving 
aspirin had lower all-cause mortality (1.3% versus 19.5%; difference 11.6%, 95% CI 
3.7-19.5) and lower mortality due to cardiovascular, cerebrovascular and 
gastrointestinal complications when compared to placebo (1.3% versus 10.3%; 
difference 9%, 95% CI 1.7-16.3) (Sung et al 2010b). One could hypothesise from the 
results that bleeding may increase the activity of platelets and as a result lead to 
higher rates of thrombotic events. 
A subsequent study from Norway investigated platelet function in gastrointestinal 
bleeding (Kringen et al 2011). They found that patients with gastrointestinal bleeding 
had lower arachidonic acid (AA) induced platelet aggregation and lower AA- and 
collagen-induced p-selectin expression (assessed by flow cytometry) when compared 
with healthy controls. However, the patients included in this study had either upper or 
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lower gastrointestinal bleeding and were not age-matched. Patients with bleeding 
related to alcohol abuse were also included, a group of patients known to have 
problems with platelet number and function (Miceli et al 2003; Ogasawara et al 2005; 
Panasiuk et al 2005; Witters et al 2008; Zhang et al 2000). In terms of absolute 
platelet numbers, this study found that patients suffering from gastrointestinal 
bleeding have lower numbers when compared to healthy controls (Kringen et al 
2011).  
 
1.4.3 Platelets in cardiovascular disease 
Platelet activation has been implicated in a number of cardiovascular disorders, e.g. 
acute coronary syndromes, recurrent ischaemic events following angiography, stroke, 
hypertension and peripheral vascular disease (Braunwald et al 2001; Chung and Lip 
2006; McCabe et al 2005; Neumann et al 1997; Ott et al 1996). Even patients with 
stable coronary artery disease have activated circulating platelets (Furman et al 1998). 
Platelets, with fibrin, are predominant components of the thombi that occludes 
arteries, but may also participate in the development and progression of the 
atherosclerotic plaques. Thus, platelets are central to the process of atherothrombosis 
(Gawaz et al 2005; Jennings 2009; Ruggeri 2002). 
Platelets play a role in the initiation of the atherosclerotic lesion formation, but 
contribute to plaque progression as well (Braunwald et al 2008). Platelets do this by 
participating in the inflammatory and matrix-degrading processes of coronary 
atherosclerosis (Massberg et al 2003). 
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Persistent platelet activation poses a serious problem among patients with ACS and 
those who have undergone PCI, placing them at risk for ischaemic events and 
subacute stent thrombosis (Braunwald et al 2008).  
As a result of this knowledge, patients with ACS receive treatment targeting platelets 
and their activation. Numerous antiplatelet agents are now available against differing 
therapeutic targets within the platelet and with different risk/benefit profiles. They are 
widely used in the primary and secondary prevention of cardiovascular disease. 
1.  Aspirin – the ‘reference’ antiplatelet agent. The mechanism of action of 
aspirin lies in its ability to irreversibly block cyclooxygenase (COX)-1, 
which inhibits the production of thromboxane A2 (Coccheri 2010). Aspirin 
resistance is associated with an increase in the risk of death, myocardial 
infarction and thromboembolic stroke (Grinstein and Cannon 2012; 
Kasotakis et al 2009). 
2.  Thienopyridines e.g. clopidogrel, prasugrel, ticlopidine. This class of drugs 
act by irreversibly inhibiting ADP binding to P2Y12 receptors on the 
platelet surface. Clopidogrel is more effective than aspirin in reducing 
cardiovascular events and death (CAPRIE 1996). Again resistance to these 
medications is associated with an increased risk of cardiovascular events 
(Nguyen et al 2005; Sharma et al 2009).  
3.   Ticagrelor. This is a non-thienopyridine reversible ADP receptor blocker 
(Nawarskas and Clark 2011). Ticagrelor has been found to be superior to 
clopidogrel for patients with ACS (Cannon et al 2010). 
4.   GPIIb/IIIa inhibitors e.g. tirofiban. This class of drug prevent platelet 
aggregation and activation by inhibiting the GPIIb/IIIa receptor on the 
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platelet surface and are therefore used as adjunctive therapy for high-risk 
patients undergoing angioplasty (Coller et al 1996). 
 
1.4.4 Markers of platelet activation and the prothrombotic state  
1.4.4.1 Platelet activation  
Platelet activation is important in the pathogenesis of cardiovascular disease and is an 
important marker in this study. There are several targets (see figure 1.5) and methods 
for measuring platelet activation. These are described as direct and indirect; direct 
methods are useful in monitoring rapid changes in platelet activation status, whereas 
indirect methods refer to the measurement of modified metabolites of activated 
platelets in either plasma or urine (Tan and Lip 2005).  
The direct and indirect methods for studying platelet activation are discussed below 
(Mylotte et al 2011; Tan and Lip 2005). 
Direct methods: 
1. Electron microscopy – this can be used to study the changes in platelet shape 
and vesiculation. However, it is a costly and time-consuming method. 
2.  Flow cytometry – this is the most widely used technique to study platelet 
activation as it is simple, quick to perform and very sensitive to picking up as 
little as 1% of activated platelets (Shattil et al 1987). In essence, 
fluorochrome-conjugated monoclonal or polyclonal antibodies directed 
against platelet glycoproteins or their receptor-ligands are used in 
combinations that allow simultaneous identification of platelets in whole 
blood with sensitive analysis of platelet antigen expression (Schmitz et al 
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1998). This suspension is then passed through a laser beam in the flow 
cytometer which detects those platelets staining positive for the specific 
antibodies and expresses this as a percentage and as mean fluorescent 
intensity (MFI). In addition, the size of the platelet can be judged by the 
forward scatter (FSC) and the granularity by side scatter (SSC). Examples of 
fluorochrome-conjugated antibodies include CD62P, recognising platelet 
surface P-selectin, and PAC-1, which is an antibody that recognises an 
epitope on the glycoprotein GPIIb/IIIa complex of activated platelets (Lu and 
Malinauskas 2011). 
Indirect methods measure metabolites of platelet activation. This can be achieved by 
techniques such as enzyme-linked Immunosorbent assay (ELISA). These assays are 
not as sensitive to dynamic changes in platelet activation as the direct methods. The 
metabolites commonly measured are β-thromboglobulin, platelet factor 4, P-selectin 
and thromboxane A2 (Mylotte et al 2011; Tan and Lip 2005).  
 
1.4.4.2 Prothrombotic markers 
Biomarkers of specific interest (proinflammatory and prothrombotic) with regards to 
this work will be discussed here. 
P-selectin 
P-selectin (also known as CD62P) is worth particular attention. It is the largest of the 
selectins, with a mass of 140 kDa and is a component of the membrane of the alpha 
and dense granules of platelets (Blann et al 2003).  P-selectin becomes present on the 
surface of platelets and endothelial cells following activation and is a cell adhesion 
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molecule. P-selectin binds to P-selectin glycoprotein ligand-1 (PSGL-1) which is 
expressed on almost all leukocytes, which leads to adhesion between these molecules. 
P-selectin is also important for inter-platelet aggregation (Blann et al 2003). Raised 
levels of P-selectin are associated with adverse cardiovascular risk (Blann et al 1997; 
Hillis et al 2002; Ridker et al 2001). 
 
Interleukin-6 
Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine (Abeywardena et 
al 2009; Simpson et al 1997). IL-6 plays a central role in diverse host defence 
mechanisms such as the immune response, haematopoiesis and acute-phase reactions 
(Simpson et al 1997). It is commonly produced at local tissue sites and is released in 
almost all situations of homeostatic perturbation, such as endotoxaemia, trauma and 
acute infection (Streetz et al 2000). Increased levels have been associated with a 
variety of pathologies such as cancer and cardiovascular disease (atherosclerosis and 
myocardial infarction) (Abeywardena et al 2009; Waldner et al 2012). IL-6 is the key 
cytokine responsible for the stimulus of synthesis and secretion of CRP. IL-6 activates 
cell surface signalling via the assembly of IL-6, the IL-6 receptor (IL-6R) and the 
signalling receptor glycoprotein 130 (Abeywardena et al 2009). IL-6 activates the 
membrane-bound receptor in hepatocytes and leucocytes, thereby initiating 
downstream proinflammatory cascades that increase hepatic production of C-reactive 
protein, fibrinogen and other acute-phase reactants (Sarwar et al 2012). These 
pathways have a causal association with coronary artery disease and could be a novel 
therapeutic approach to preventing coronary artery disease (Hingorani and Casas 
2012; Sarwar et al 2012).  
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Von Willebrand Factor 
Von Willebrand Factor (vWF) is a multimeric glycoprotein encoded on chromosome 
12 and is produced almost exclusively by endothelial cells (Speil et al 2008). It plays 
a vital role in mediating platelet adhesion to arterial walls suggesting a possible 
contributory prothrombotic role (Constans et al 2006). It is an essential factor in 
primary haemostasis, and a hereditary deficiency of vWF is consequently associated 
with an increased likelihood of bleeding (Jansson et al 1991). vWF has a role in both 
platelet adhesion and aggregation, and has been found to be elevated in various 
conditions of endothelial damage. It has therefore been proposed as a useful marker of 
endothelial dysfunction with multiple studies showing that vWF is a predictor of 
cardiovascular events (Jansson et al 1991; Spiel et al 2008; Thompson et al 1995). IL-
6 and vWF have been used as part of a biomarker panel to help predict adverse 
cardiovascular prognosis (Omicron Hartaigh et al 2013). 
 
D-dimer 
D-dimer is derived from the breakdown of fibrinogen and is termed a fibrin 
degradation product. It is a biomarker of fibrin turnover and hence, thrombosis 
(Danesh et al 2001; Wang et al 2006). It is formed from the activation of the 
following enzymes in sequence; thrombin, factor XIIIa and plasmin (Adam et al 
2009). D-dimer is only present in circulating blood in response to activation of the 
coagulation cascade, and is a specific marker of fibrin clot formation and fibrinolysis 
(Adam et al 2009).  
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Elevated d-dimers levels have been shown to predict future myocardial infarction in 
the elderly and overall cardiovascular mortality (Cushman et al 1999; Danesh et al 
2001; Folsom et al 2009; Lowe et al 1998; Lowe et al 2004).  
Elevated d-dimer levels are also associated with a number of conditions such as 
venous thromboembolism, functional decline in patients with peripheral vascular 
disease, stroke and cancer mortality (Christersson et al 2014; Folsom et al 2009; 
Folsom et al 2016; Halaby et al 2015; McDermott et al 2003; Wiseman et al 2014). In 
apparently healthy individuals a raised d-dimer is independently associated with all-
cause mortality (Di Castelnuovo et al 2013). 
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1.5 Study hypothesis 
 
• The use of risk scores for acute upper gastrointestinal bleeding in real-life 
practice is poor. The use of the Blatchford score is better able to identify 
patient’s suitable for outpatient management than the Rockall score. To 
demonstrate the presence of diurnal and seasonal variation in the presentation 
of acute upper gastrointestinal bleeding. 
• Clinically significant bleeding (acute upper gastrointestinal bleeding, bleeding 
in the context of an ACS) leads to long-term, as well as short-term increased 
platelet activation and other prothrombotic markers, which may contribute to 
the poor clinical outcomes, including thrombotic events observed in these 
conditions 
 
1.6  Study aims 
 
1. To assess the management of patients with acute upper gastrointestinal 
bleeding including the use of risk stratification to assess patients for early 
discharge 
2. To assess for a diurnal and seasonal variation in the presentation of acute 
upper gastrointestinal bleeding 
3. To characterise temporal changes in platelet activation and other 
prothrombotic markers in the following patients: 
a) Acute upper gastrointestinal bleeding  
b) Bleeding in the context of acute coronary syndrome  
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CHAPTER 2 – MATERIALS AND METHODS 
 
2.1  Materials 
2.1.1  General Reagents 
Reagents were obtained from the following sources: 
• Abcam, Cambridge, UK 
D-dimer ELISA kit (Mouse monoclonal anti-D-dimer antibody) 
• Abnova, Taipei, Taiwan 
Fibrinogen (Human) ELISA kit 
• Alpha Laboratories, Hampshire, UK 
200 µL yellow pipette tips, 1250 µL clear pipette tips  
• Becton Dickinson, Oxford, UK 
Polystyrene round-bottom tubes (5 mL), FACS Flow, FACS Clean, Lysing 
solution, venous blood collection tubes (3.8% citrate, CTAD, EDTA, serum) 
• Bio/Data Corporation, Pennsylvania, USA  
Arachidonic acid 5 mg/mL 
• Dako, Ely, Cambridgeshire, UK 
Cytocount (Count control beads), Polyclonal rabbit anti-human vWF; 
Polyclonal rabbit anti-human vWF/HRP (Horse Radish Peroxidase) 
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• Invitrogen, Paisley, Renfrewshire, UK 
Phosphate buffered saline (PBS) 
• Labsystems, Basingstoke, Hampshire, UK 
0.5-10 µL, 40-200 µL, 200-1000 µL single channel pipettes, 40-200 µL eight 
channel pipette 
• R & D Systems, Abindgon, UK 
Hydrogen peroxide; IL-6 Immunoassay ELISA kit; Human P-Selectin 
Immunoassay ELISA Kit; sulphuric acid; tetramethylbenzidine 
• Sigma-Aldrich, Dorset, UK 
L-arginyl-glycyl-L-aspartyl-L-serine (RGDS); Adenosine diphosphate (ADP); 
Bovine serum albumin; Citric acid; Washing manifold; phosphate buffered 
saline tablets; Triton X-100; fibrinogen; Hydrogen peroxide (30% w/w); 
Hydrochloric acid; Sodium carbonate; Sodium hydrogen carbonate; Sodium 
hydrogen phosphate; Ortho-phenylene diamine 
• Thermo Electron Corporation, Basingstoke, Hampshire, UK 
Flat-bottomed 96 well microtitre plates 
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2.1.2  Antibodies 
The antibodies utilised for flow cytometry are shown in table 2.1 below along with 
their source. 
 
Table 2.1 Antibodies and isotype controls used for flow cytometry 
TARGET 
ANTIGEN 
FLUROCHROME CATALOGUE 
NUMBER & 
CLONE 
TYPE SUPPLIER 
CD42a (Anti-
gpIX) 
PerCP 340537 
Beb1 
Mouse 
IgG1 
Becton 
Dickinson, 
Oxford, UK 
CD62P APC 550888 
AK-4 
Mouse 
IgG1 
Becton 
Dickinson, 
Oxford, UK 
PAC-1 FITC 340507 
PAC-1 
Mouse 
IgM 
Becton 
Dickinson, 
Oxford, UK 
FITC Mouse 
IgM, Isotype 
Control 
FITC 551448 
G155-228 
Mouse 
IgM 
Becton 
Dickinson, 
Oxford, UK 
APC Mouse 
IgG1 Isotype 
Control 
APC IC0002A Mouse 
IgG1 
R&D Systems, 
Abingdon, 
Oxford, UK 
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CD144 PE FAB9381P 
123413 
Mouse 
IgG2B 
R&D Systems, 
Abingdon, 
Oxford, UK 
CD42b APC 551061 
HIP1 
Mouse 
IgG1 κ 
Becton 
Dickinson, 
Oxford, UK 
CD14 PerCP FAB3832C 
134620 
Mouse 
IgG1 
R&D Systems, 
Abingdon, 
Oxford, UK 
APC = allophycocyanin; PerCP = Peridininchlorophyll Protein Complex; FITC = 
fluoroscein isothiocyanate; PE = phycoerythrin 
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2.2 Venepuncture 
2.2.1 Venepuncture technique 
A standardised venepuncture protocol was used for all patients in accordance to local 
guidelines. 
All subjects were required to rest for 10 minutes prior to venepuncture to avoid 
artefactual platelet activation that can be influenced by adrenergic hormones and 
physical exercise (Hjemdahl et al 1991). Blood samples were drawn from an 
antecubital fossa vein into vacutainers using a 20-gauge needle with minimal stasis 
(Janes and Goodhall 1994). The initial aliquots were used to obtain EDTA and serum 
samples to minimise artificial platelet activation as a result of venepuncture. 
Subsequent aliquots were collected in citrate and CTAD (citrate, theophylline, 
adenosine and dipyridamole) vacutainers to assess platelet activation via flow 
cytometry (citrate) and ELISA (CTAD). Citrated blood was used in accordance to 
manufacturer’s guidelines (BD Biosciences). CTAD vacutainers were used as 
although EDTA vacutainers have been used previously, PAC-1 will not bind to 
EDTA-treated blood (Shattil et al 1986). 
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2.3  Flow Cytometry for the determination of platelet 
activation 
An assay was developed to accurately measure platelet activation. Flow cytometry is 
a sensitive and reliable method to directly measure expression of activation-dependent 
surface markers on platelets in whole blood with minimal handling therefore greatly 
reducing the chances of in vitro platelet activation. 
Flow cytometry was performed in accordance with the consensus document for the 
flow cytometric characterisation of platelet function (Schmitz et al 1998).   
 
2.3.1  Technique 
Venous blood was taken as described in 2.2.1. Citrated samples were used for flow 
cytometric analysis of platelet activation. EDTA vacutainers were avoided as PAC-1 
binding to the fibrinogen receptor is both pH and calcium sensitive (Shattil et al 
1986). As a result PAC-1 does not bind with EDTA-treated blood. 
CaliBRITE three-colour beads and FACSComp software were used to set 
photomultiplier tube voltages, fluorescence compensation, spectral overlap and 
sensitivity. 
After incubation data acquisition and analysis were performed with CELLQuest 
software version 3.1 in the flow cytometer (FACSCalibur, BD Biosciences, Oxford, 
UK). Ten thousand activation-independent platelet events were collected for each 
sample.  
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The FACSCalibur was calibrated using FACSComp software with CaliBRITE beads 
on a daily basis. 
 
2.3.2 Identification of platelets 
Platelets were identified on the basis of their forward (FSC) and side scatter 
characteristics (SSC) and the presence of CD42a, a pan-platelet marker. FSC and SSC 
were set on logarithmic gains.  
 
2.3.3  Titration of antibodies 
Platelet activation was assessed by the presence of the monoclonal antibodies PAC-1 
and CD62P. The concentration of all antibodies used for activation analysis has to be 
titrated towards a saturating titre. Antibodies at varying concentrations were titrated 
against a blood sample stimulated maximally with the addition of ADP (2 x 10-4 M) – 
see 2.3.4 – for use in all future experiments. 
The following volumes of antibodies were optimal for all future flow cytometry 
experiments:  
• 3 µL CD42a-PerCP 
• 5 µL CD62P-APC  
• 5 µL PAC-1-FITC  
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2.3.4 Platelet stimulation with adenosine diphosphate 
Various strengths of ADP were used to stimulate whole blood, ranging between (0 – 2 
x 10-4 M), using the following method: 
• Within 10 minutes of venepuncture, 50 µL of ADP was pipetted into a test 
tube. 
• 0.45 mL of whole blood was added and gently swirled to mix. 
• This was incubated at room temperature for 2 minutes. 
• The sample was analysed immediately. 
For the purpose of the study, 2 x 10-4 M ADP was used throughout as this was 
adequate for maximal platelet activation in all future experiments. Stimulating the 
platelets will serve as a positive control in the experiments and measure the reactivity 
of platelets to an agonist in various clinical conditions.  
 
2.3.5  Platelet stimulation with arachidonic acid 
Various strengths of arachidonic acid (AA) were used to stimulate whole blood using 
the following method: 
• Within 10 minutes of venepuncture, 2.6 µL of AA was pipetted into a test 
tube. 
• 98 µL of whole blood was added and gently swirled to mix. 
• This was incubated at room temperature for 5 minutes. 
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• The sample was analysed immediately. 
Given the availability of ADP and the large intra-assay variability found with AA, 
ADP was used in all future experiments. 
 
2.3.6  Intra-assay Variability 
Intra-assay reproducibility is 3.7% for CD62P and 16.9% for PAC-1 positive platelets 
at rest and 0.9% for CD62P and 2.8% for PAC-1 when stimulated with ADP. 
 
2.3.7  Summary of technique to determine platelet activation with flow 
cytometry 
Within 10 minutes of collection 5µL of 3.8% citrated whole blood was incubated at 
room temperature for 15 minutes with monoclonal mouse-antihuman antibodies 
against constitutively expressed platelet marker CD42a-PerCP (Clone Beb1, BD), and 
markers of platelet activation PAC-1-FITC (Clone PAC-1, BD), and CD62P-APC 
(Clone AK-4, BD). In parallel negative control samples including L-arginyl-glycyl-L-
aspartyl-L-serine (RGDS, Sigma-Aldrich, Dorset, UK) and IgG1-APC isotype control 
(R&D Systems, Abingdon, UK) were utilised. Incubation was terminated by 1:20 
dilution in pH 7.2 phosphate buffered saline (PBS, Invitrogen, Paisley, UK). 
Response to an agonist, in this case adenosine diphosphate (ADP), was assessed by 
stimulating 3.8% citrated blood with 2x10-4M ADP (Sigma-Aldrich) for 2 minutes 
prior to incubation with antibodies as described above. 
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After incubation, samples were analysed using a FACSCalibur flow cytometer (BD). 
Platelets were identified on the basis of their forward and side scatter properties and 
the presence of the CD42a platelet-specific marker. CD62p and PAC-1 expression 
were measured by mean fluorescence intensity (MFI) and the percentage of platelets 
expressing these markers was recorded. 
Example flow cytometry figures of isotype controls, resting platelets and platelets 
stimulated with ADP are shown in figures 2.1, 2.2 and 2.3.
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Figure 2.1 Assessment of platelet activation using flow 
cytometry – isotype control. This figure shows an example of a 
typical flow cytometry plot with isotype control staining. The top 
right box shows platelets staining for CD42a, a pan-platelet marker. 
The bottom left corner box shows platelets staining postive for 
either CD62P, PAC-1, or both. As expected with an isotype control 
those staining positive is minimal. 
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Figure 2.2 Assessment of platelet activation using flow 
cytometry – resting platelets. As per figure 2.1, however, in this 
figure no isotype control was used. This bottom left box shows 
typical figures for staining of CD62P and PAC-1 whilst platelets 
are in a resting state (i.e. taking whole blood and running the 
analysis without any additional platelet stimulation).  
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Figure 2.3 Assessment of platelet activation using flow cytometry – 
stimulated platelets. As per figures 2.1 and 2.2. In this example 
platelets have been stimulated with 2 x 10-4 M ADP for 2 minutes. The 
bottom left box shows a right-sided shift in the staining of platelets 
indicating increased staining for both CD62P and PAC-1 as would be 
expected for stimulated platelets which have undergone activation.
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2.4  Enzyme-linked immunosorbent assay 
A brief outline of ELISA techniques will be described here, for full standard operating 
procedures refer to appendix 2. Levels of vWF, soluble P-selectin, IL-6 and 
fibrinogen were measured using commercially available ELISA kits. Experiments 
were carried out in accordance to manufacturer’s instructions. 
 
2.4.1  Determination of von Willebrand Factor 
In brief, a microtitre plate was coated with 100 µL of a dilution of the primary 
antiserum at room temperature for 60 minutes. After washing, a 1:40 dilution of 
plasma, and standards, was added in duplicate and incubated for 60 minutes. After 
washing, 100 µL of the secondary antiserum was added and incubated for 45 minutes. 
After washing, 100 µL of substrate was added and the reaction terminated with 50 µL 
hydrochloric acid. Optical densities were read at 492 nm on a microplate reader. 
 
2.4.2  Determination of soluble P-selectin 
Microtitre plates were coated with the capture antibody and incubated overnight at 
room temperature. Unbound antibody was washed, and plates blocked and incubated 
for 1 hour and washed again. Samples, and standards, were then added to the plates in 
duplicate and incubated for 2 hours at room temperature. After washing, the detection 
antibody was added and after incubating for another 2 hours streptavidin-horseradish 
peroxide was added to bind the detection antibody. After washing, 
tetramethylbenzidine substrate solution was added to the wells and a blue colour 
88 
 
developed. This reaction was stopped with sulphuric acid and optical densities were 
read using a microplate reader set to 450 nm. 
 
2.4.3 Determination of interleukin-6 
The principle for IL-6 is the same as soluble P-selectin determination (see section 
2.4.2). 
 
2.4.4 Determination of d-dimer 
In brief, 50 µL of plasma and standards was added in duplicate to pre-prepared 
microtitre plates followed by 50 µL of the antibody cocktail and incubated for 60 
minutes on a plate shaker. After washing 100 µL of substrate was added to each well 
and incubated for 10 minutes in the dark on a plate shaker.  The reaction was 
terminated with 100 µL of stop solution and placed on a plate shaker for 1 minute. 
Optical densities were read at 450 nm on a microplate reader. 
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2.5  Audit of acute upper gastrointestinal bleeding 
A retrospective observational study was undertaken on all patients admitted to 
Sandwell and West Birmingham Hospitals NHS Trust in 2009 suffering from 
AUGIB. This study was approved by SWBH NHS Trust audit department. 
Patients were identified by interrogation of the ADAM® medical documentation 
system (Fujinon Europe GmbH, Willich, Germany) database using the search: 
‘haematemesis,’ ‘melaena’ and ‘suspected upper gastrointestinal haemorrhage’ and 
Endoscopy department logbooks. Using a custom designed proforma (see appendix 3) 
data was collected from ‘Unisoft’ and hospital records including: patient 
characteristics, co-morbidities, clinical findings in order to calculate Rockall and 
Blatchford scores, use and timing of endoscopy, treatment including endoscopic and 
blood transfusion. Rebleeding and mortality rates (30 day) were also recorded.  
Audit standards were based on recent British Society of Gastroenterology (BSG) / 
Scottish Intercollegiate Guidelines Network (SIGN) Guidelines (SIGN 2008). 
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2.6 Study of platelet activation and prothrombotic 
markers 
2.6.1  Cross-sectional study 
Patients admitted to Sandwell and West Birmingham Hospitals NHS Trust with an 
ACS and a bleeding episode, and with AUGIB, were compared to control groups. All 
patients had baseline demographic details recorded including age, gender, race, BMI, 
pulse, blood pressure, smoking status and any co-morbidity. Documentation of any 
medications stopped during a period of bleeding were taken. 
Bleeding was defined according to the International Society on Thrombosis and 
Haemostasis criteria (e.g. Symptomatic bleeding in a critical area such as intracranial, 
gastrointestinal, retroperitoneal, clinically observed haemorrhage or access site 
haematoma) or covert (drop in haemoglobin [Hb] of >2g or drop in Hb needing 
transfusion of 2 or more units of blood). 
Control groups were:  
a: ACS patients with no bleeding episode,  
b: Patients having endoscopy but no bleeding or cardiac disease,  
c: Stable patients with controlled angina who have undergone PCI over 6 months 
previously. 
Control groups were age and sex matched. 
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2.6.2  Longitudinal study 
Patients admitted with a bleeding episode had blood samples taken on admission, 4 
and 12 weeks later with patients followed up clinically for a period of 6 months. 
Episodes of further cardiovascular and bleeding episodes were recorded in addition to 
any other hospital admissions for other reasons. 
Markers of platelet activation were compared between the admission and blood tests 
taken at 3 months, to see if any changes seen was prolonged, and whether it was 
different from the control groups.  
 
Inclusion Criteria: 
• Participant is willing and able to give informed consent for participation in the 
study 
• Male or Female, aged 18 years or above 
 
Exclusion Criteria: 
The participant may not enter the study if any of the following apply: 
• Patient on warfarin or equivalent oral anticoagulation 
• Previous gastrointestinal haemorrhage in past 3 months 
• Previous ACS and PCI in last 3 months 
• Major trauma in last 3 months 
• Surgery in last 3 months 
• Current malignancy 
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• Current sepsis 
• Active systemic inflammatory disease (e.g. rheumatoid arthritis) 
• Pregnancy 
• Liver disease 
 
2.7 Data analysis and study statistics 
Statistical advice was obtained from Dr Andrew Blann, Senior Lecturer and Fellow of 
the Royal Statistical Society. 
The sample size calculation was based on plasma levels of d-dimers (DDs), which 
would therefore be the test statistic. The local method (immunturbidimetry, Stago) 
takes as cut off value of 0.5 fibrinogen equivalent units/mg/mL (FEUs/mg/mL) as 
being raised and of clinical significance. A reference range of median 0.25 
(interquartile range 0.18-0.26) FEUs/mg/mL and a pathological levels of 0.6 (0.58-
0.66) FEUs/mg/mL to be expected from patients with cardiovascular disease was 
modelled.  
It was hypothesised that levels of DDs will remain high at 3 months compared to 6 
weeks (i.e. statistically unchanged), in those patients who have had PCI and who have 
subsequently suffered a haemorrhagic endpoint. This group was compared to the 
group of PCI patients whose high DDs at 6 weeks (i.e. in the region of 0.60 (0.58-
0.65) FEUs/mg/mL) will resolve at 3 months in falling by 50% towards the reference 
range at, i.e. to 0.30 (0.30-0.50) FEUs/mg/mL. This drop is significant at p<0.01 and 
1-beta = 0.8 if good paired data from n=25 are analysed. To achieve a difference of 
p<0.05 and a power of 0.80, 25 subjects are required in each group. However, 
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recognising the possibility of drop out and increased variability in a clinical setting, 
the aim was to collect samples from 30 patients per group. 
Following application of the Shapiro-Wilk W test, to determine distribution, non-
categorical data distributed normally was analysed by t test, and data distributed non-
normally by the Mann-Whitney U test. Correlations were sought with Spearman’s rank 
method. Categorical data (e.g. sex and smoking) was analysed by the chi-squared test. 
Power calculations were performed on Minitab 16 software, statistical analysis of the 
raw data was performed with SPSS 19.0 software. 
A probability of 0.05 was considered as statistically significant. 
 
2.8 Ethical considerations 
The study was conducted in accordance with the declaration of Helsinki. Ethical 
approval has been obtained from the Warwickshire Research Ethics Committee: 
reference number 09/H1211/67.  
Written informed consent was obtained from all patients. 
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CHAPTER 3 – AUDIT OF ACUTE UPPER 
GASTROINTESTINAL BLEEDING 
 
3.1  Introduction 
Acute upper gastrointestinal bleeding (AUGIB) poses a significant health problem 
associated with significant costs to the NHS (Klein and Gralnek 2015). Across Europe 
the incidence varies between 50-170 per 100000 population (Blatchford et al 1997; 
Button et al 2011; Hearnshaw et al 2010a; Rockall et al 1995). 
Overall in the UK, AUGIB accounts for over 9000 deaths per annum (Crooks et al 
2009). In the UK, mortality due to AUGIB is between 8.2-13.1% (Blatchford et al 
1997; Button et al 2011; Crooks et al 2011). Mortality figures appear to be decreasing 
for variceal haemorrhage but only minimally changing for non-variceal haemorrhage. 
From 1999-2007, 28-day mortality for non-variceal haemorrhage was reduced from 
14.7% to 13.1%, and for variceal reduced from 24.6% to 20.9% (Crooks et al 2011). 
The aim of this retrospective study was to assess the management of AUGIB in 
SWBH NHS Trust, including the use of risk scoring systems (i.e. Rockall and 
Glasgow Blatchford scores) and the need for intervention (i.e. endoscopic therapy or 
transfusion). A further objective was to study the diurnal and seasonal variation of the 
presentation of AUGIB given that many diseases related to platelet activation or 
function show diurnal variability (e.g. ACS, sudden cardiac death, stroke), with a 
peak incidence in the morning hours (Marsh et al 1990; Muller et al 1985; Muller et 
al 1987; Quyyami 1990; Tofler et al 1987; Willich et al 1987; Zarich et al 1994). A 
European study found biphasic peaks in peptic ulcer bleeding with haematemesis 
incidence peaking at both 6:45AM and 6:45PM (Minoli et al 1994). However, data 
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from China has highlighted a diurnal variation in the presentation of AUGIB with a 
peak incidence in the nighttime hours (Du et al 2010). There has been recent interest 
into the possibility of poor outcomes associated with blood transfusion in patients 
with AUGIB, therefore, this area will also be addressed (Hearnshaw et al 2010b). 
 
3.2 Methods 
This was a retrospective study of all patients presenting with AUGIB requiring an 
endoscopy to SWBH NHS Trust, between 1st January and 31st December 2009. 
SWBH NHS Trust serves an urban population over approximately 500000 over two 
hospital sites. Patients were identified using the ADAM® medical documentation 
system (Fujinon Europe GmbH, Willich, Germany) and Endoscopy department 
logbooks. 
A 3 page custom-designed questionnaire (see appendix 3) was used to collect the 
following information on patients; baseline demography, co-morbidity, endoscopic 
diagnosis and therapy, transfusion requirements, length of stay and 30 day mortality. 
Data was collected to allow the calculation of the Glasgow Blatchford and Rockall 
scores. Patients were followed up for 30 days to assess mortality at this time point. 
Audit standards for the management of AUGIB were taken from the current 
guidelines approved by the British Society of Gastroenterology (SIGN 2008). 
To investigate for seasonal variation of the presentation of AUGIB the year was split 
into the four seasons; spring (March, April and May), summer (June, July and 
August), autumn (September, October and November) and winter (December, January 
and February). To investigate for diurnal variation of the presentation of AUGIB, the 
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day was split into equal 6-hour periods (00:01-06:00; 06:01-12:00; 12:01-18:00; 
18:01-00:00). For new admissions, the time was recorded as the time of presentation 
to the Emergency Department; for established inpatients the time was recorded as the 
time of onset of symptoms.  
 
Statistical analysis 
Data was analysed using SPSS (Statistical Package for Social Sciences) software 19 
(SPSS Inc., Chicago, Illinois), unless otherwise stated. Diurnal and seasonal 
differences in presentation were analysed using the χ2 (chi-squared) test; differences in 
Rockall and Glasgow Blatchford scores were analysed using the Kruskal-Wallis test, 
followed by the Mann Whitney U test, with Bonferroni correction, to assess 
differences between individual groups. Trend changes in scores over the 24 hour 
period were determined by Altman’s linear ordered groups method. A p-value of 
<0.05 was considered as statistically significant. 
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3.3 Results 
3.3.1 Baseline patient characteristics 
The initial search drew results of 474 patients who were admitted suffering from an 
AUGIB. Four sets of notes could not be retrieved and as a result they were excluded 
from all subsequent analysis. Data relating to 470 patients were included in the 
analysis.  
The baseline patient characteristics are shown in Table 3.1. Of all cases of AUGIB 
67.2% (n=316) were male and 32.8% (n=154) were female. The median age of the 
patients was 68 years (IQR 40-96) with an age range of 18-99 years. With regards to 
ethnicity, 70.6% (n=332) were Caucasian, 17.7% (n=83) Asian, 10.4% (n=49) Afro-
Caribbean, with the ethnicity unknown in 1.3% (n=6) of cases. 
The age distribution of cases was as follows: 
• <60 years 36.2% (n=170) 
• 60-79 years 40.8% (n=192) 
• ≥80 years 23.0% (n=108) 
Current inpatients accounted for 23.4% (n=110) of cases. Patients were admitted 
during a weekday in 78.5% (n=369), with 21.5% (n=101) admitted at the weekend. 
Delayed presentation to hospital was defined as greater than 24 hours from symptom 
onset to hospital attendance. This occurred in 34.7% (n=163) of cases. 
Haematemesis was the presenting symptom in 70.6% (n=332) of cases, melaena in 
58.3% (n=274) and syncope in 11.3% (n=53). A digital rectal examination was 
98 
 
performed in 74.5% (n=350) of cases. Alcohol intake was documented 76.6% 
(n=360) of the time. 
Pre-admission medications are shown in table 3.1. However, 14.5% (n=68) of patients 
were on prophylactic enoxaparin at the time of AUGIB. It should be noted that 54.5% 
(n=256) of patients received PPI therapy pre-endoscopy. This was administered 
intravenously in 69.5% (n=178) and orally in 30.5% (n=78) of cases. In the case of a 
potential variceal haemorrhage (70 cases) terlipressin was given 58.6% (n=41) of the 
time. 
 
3.3.2 Blood transfusion 
A transfusion of packed red cells was given to 51.7% (n=243) of patients. These 
patients were older than those who did not require transfusion (mean age 67.2 ± 16.0 
years compared to 60.5 ± 20.8 years; P<0.001).  As would be expected those who 
received a transfusion had a lower haemoglobin level than those who did not (mean 
Hb 7.6 ± 2.0 g/dL compared to 12.6 ± 2.5 g/dL; P<0.001). 
 
Mortality and blood transfusion 
Of those patients who received a blood transfusion (n=243), 30 day mortality was 
21.0% (n=51). Of those who did not receive a blood transfusion (n=227), 30 day 
mortality was 10.1% (n=23). There was a significantly increased 30 day mortality for 
those receiving transfusion; 21% versus 10.1%; P=0.001. 
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Table 3.1 Baseline patient characteristics of patients with acute upper 
gastrointestinal bleeding 
Characteristic Percentage (n=470) 
Gender  
Male 67.2 (n=316) 
Female 32.8 (n=154) 
Age  
Overall (mean ± standard deviation) 64.0 (± 18.8) 
Male 62.5 (± 18.5) 
Female 67.1 (± 19.3) 
Admission status  
New admission 76.6 (n=360) 
Co-morbidity  
IHD 14.5 (n = 68) 
Cardiac failure 8.1 (n = 38) 
Cancer 11.7 (n=55) 
Hypertension 36.4 (n = 171) 
Stroke 8.7 (n = 41) 
Diabetes 19.4 (n = 91) 
AF 9.6 (n = 45) 
Pre-admission medication  
Aspirin 32.6 (n=153) 
Clopidogrel 7.9 (n=37) 
NSAIDS 11.3 (n=53) 
Warfarin 6.2 (n=29) 
PPI 30.9 (n=145) 
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3.3.3 Pre-endoscopy risk assessment  
Only 20% (n=94) had a pre-endoscopy risk score documented.  
Rockall scores for patients are shown in table 3.2. A Rockall score of 0 accounted for 
13.8% (n=65) of cases. 
Glasgow Blatchford scores are shown in table 3.3 and figure 3.1. A Glasgow 
Blatchford score of 0 accounted for 6.0% (n=28) of cases. 
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Table 3.2 Pre-endoscopy Rockall scores 
Pre-endoscopy Rockall score Percentage 
0 – 1 34.7 (n=163) 
2 – 3 33.0 (n=155) 
4 – 5 28.3 (n=133) 
6 – 7 3.6 (n=17) 
Unknown 0.4 (n=2) 
 
This table demonstrates the pre-endoscopy Rockall scores of patients admitted with 
AUGIB. Approximately one third of patients admitted had a low risk pre-endoscopy 
Rockall score of 0-1. 
 
Table 3.3 Glasgow Blatchford scores 
Blatchford score Percentage 
0 – 3  19.2 (n=90) 
4 – 7  20.6 (n=97) 
8 – 11  24.9 (n=117) 
12 - 15 29.6 (n=139) 
16 - 19 5.3 (n=25) 
Unknown 0.4 (n=2) 
This table demonstrates the Glasgow Blatchford scores of patients admitted with 
AUGIB. The spread of Glasgow Blatchford scores are evenly spread with a lower 
proportion presenting with a very high Blatchford score.  
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Figure 3.1 Glasgow Blatchford scores  
A significant proportion of patients presenting with AUGIB have a low risk GBS of zero and a large proportion have high risk scores (i.e. GBS 
greater than 12). Very few patients are admitted with very high risk bleeds. 
Blatchford Score 
Number of patients 
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3.3.4 Pre-endoscopy risk and need for intervention 
Pre-endoscopy risk assessment can be used to assign a patients risk of mortality or 
need for intervention. The need for intervention for the patients in this cohort, 
dependent on their Rockall or Glasgow Blatchford score, was assessed. 
The need for intervention (i.e. transfusion, endoscopic therapy or surgery) and 
mortality for a given GBS is shown in table 3.4 and figure 3.2. Of note, patients with 
a GBS ≤ 2 had no need for intervention and had no mortality (figure 3.2). This group 
of patients accounts for 14.7% (n=69) of all patients admitted with AUGIB. The need 
for intervention increased with a higher GBS with patients potentially requiring more 
than 1 intervention e.g. undergo endoscopic therapy and need a blood transfusion. 
Those patients with a Blatchford score ≤ 2 were younger than those with a score ≥ 2, 
with a mean age of 44.1 ± 17.5 years versus 67.4 ± 18.8 years (P<0.001).  
The need for intervention, for a given pre-endoscopy Rockall score is shown in table 
3.5 and figure 3.3. It should be noted, that those patients with a Rockall score of 0 (i.e. 
low risk) had a need for intervention in a number of cases; 13.8% (n=9) required a 
blood transfusion and 6.2% (n=4) received endoscopic therapy. There were however, 
no deaths in this group. A post-endoscopy risk score of 0-1, shown in table 3.6, was 
associated with fewer interventions (16.4% had a transfusion and 4.1% received 
endoscopic therapy) but of note, there were no deaths at 30 days. 
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Figure 3.2 Glasgow Blatchford score and subsequent need for intervention  
Patients with a GBS of 2 or less did not require an intervention, such as blood transfusion or endoscopic therapy. 
Blatchford Score 
Number of patients 
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Table 3.4 Glasgow Blatchford score and need for intervention 
Score No. of 
pts 
Age 
(mean 
±SD) 
Blood 
transfusion  
(%) 
Endoscopic 
therapy 
(%) 
30-day 
mortality 
(%) 
0 28 42.4±20.3 0 0 0 
1 24 42.2±17.0 0 0 0 
2 17 49.6±20.6 0 0 0 
3 21 57.7±19.4 10 10 14 (5 from GIB) 
4 23 63.4±19.6 4 22 13 (4 from GIB) 
5 21 68.5±17.2 5 24 5 
6 23 62.7±21.4 22 13 9 
7 30 61.0±18.1 53 20 10 
8 22 69.8±18.4 36 36 18 
9 25 68.0±13.1 52 24 8 
10 27 68.6±13.2 63 30 4 
11 43 70.7±14.5 88 37 14 (5 from GIB) 
12 41 70.9±16.0 83 37 29 (5 from GIB) 
13 38 68.1±15.5 84 39 24 (8 from GIB) 
14 35 66.1±15.1 94 37 17 (6 from GIB) 
15 25 71.3±13.8 96 72 36 (16 from 
GIB) 
16 12 71.7±18.1 100 42 50 (17 from 
GIB) 
17 7 70.7±11.0 100 43 0 
18 3 71.7±10.4 100 33 0 
19 3 65.7±16.4 100 33 33 
Unknown 2 83.5±7.8 50 0 50 
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Table 3.5 Pre-endoscopy Rockall scores and need for intervention 
Score No. of pts Age 
(mean 
±SD) 
Blood 
transfusion 
(%) 
Endoscopic 
therapy 
(%) 
30-day 
mortality 
(%) 
0 65 37.4±12.1 14 6 0 
1 98 50.2±16.0 35 17 2 (1 from GIB) 
2 82 74.2±15.8 61 27 16 (4 from GIB) 
3 73 69.9±12.0 71 37 11 (3 from GIB) 
4 77 69.7±16.8 62 44 22 (4 from GIB) 
5 56 67.7±13.5 77 38 39 (14 from 
GIB) 
6 16 81.4±7.7 75 25 31 
7 1 89.0±0.0 100 100 100 
Unknown 2 83.5±7.8 50 0 50 
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Figure 3.3 Need for intervention based on the pre-endoscopy Rockall score 
In patients with a low risk pre-endoscopy Rockall score (i.e. 1) a significant proportion of patients required either blood transfusion or 
endoscopic intervention. This is in contrast to the GBS where patients with a score of 0 did not require any intervention. 
Rockall Score 
Number of patients 
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Table 3.6 Post-endoscopy Rockall score and need for intervention 
Score No. of pts Age 
(mean 
±SD) 
Blood 
transfusion 
(%) 
Endoscopic 
therapy 
(%) 
30-day 
mortality 
(%) 
0 23 64.0±19.0 17 0 0 
1 50 63.7±19.1 16 6 0 
2 74 63.4±18.9 31 5 1 
3 59 64.0±18.9 59 10 10 (2 from 
GIB) 
4 57 66.7±18.9 54 32 14 (5 from 
GIB) 
5 75 68.9±18.9 63 40 19 (3 from 
GIB) 
6 57 69.4±18.8 79 47 23 (5 from 
GIB) 
7 37 73.0±18.8 73 62 38 (5 from 
GIB) 
8 22 64.8±18.8 86 64 41 (23 from 
GIB) 
9 6 82.5±18.6 100 67 0 
10 1 89.0±0 100 100 100 
Unknown 9 67.6±18.8 33 0 33 (11 from 
GIB) 
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3.3.5 Timing of Endoscopy  
The timing of endoscopy is important. Patients should have an endoscopy within 24 
hours of admission. Overall, 61.3% (n=288) of patients had an endoscopy within 24 
hours. Disappointingly, a significant proportion of patients, 23.0% (n=108), waited 
greater than 48 hours for endoscopic examination. The timing of endoscopy is shown 
in table 3.7. 
Out of hours endoscopy occurred in 10.6% (n=50) of cases. The majority of cases 
took place in the endoscopy unit, 90.4% (n=425). Endoscopy was performed in the 
intensive care unit in 4.3% (n=20) and in theatres in 2.8% (n=13) of cases. 
 
Table 3.7 Timing of endoscopy 
Time to endoscopy Percentage 
<12 hours 30.2% (n=142) 
12 – 24 hours 31.1% (n=146) 
24 – 48 hours 15.7% (n=74) 
48 – 72 hours 6.8% (n=32) 
> 72 hours 16.2% (n=76) 
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3.3.6 Endoscopic diagnosis 
Data on endoscopic diagnosis are shown in table 3.8. Peptic ulcer disease was the 
most common diagnosis found on endoscopy. Of note, a normal endoscopy was found 
in 9.1% (n=43) of cases.  
 
Table 3.8 Diagnosis found on endoscopic examination 
Diagnosis Percentage (n=470) 
Peptic ulcer 34.5 (n=162) 
Varices 11.3 (n=53) 
Malignancy 1.9 (n=9) 
Oesophagitis 31.7 (n=149) 
Gastritis 23.0 (n=108) 
Duodenitis 14.7 (n=69) 
Mallory Weiss Tear 4.3 (n=20) 
Bleeding post-sphincterotomy 1.1 (n=5) 
Other* 3.0 (n=14) 
Normal 9.1 (n=43) 
*angiodysplasia, Dieulafoy lesion, aorto-enteric fistula 
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3.3.7 Endoscopic therapy 
Of all patients with AUGIB only 27.7% (n=130) required an endoscopic intervention, 
meaning that in the vast majority 72.3%, (n=340) of cases no endoscopic intervention 
was required.    
Of those patients requiring endoscopic therapy for oesophageal varices, endoscopic 
band ligation was used in 54.7% of cases (n=29). One patient (2%) had endoscopic 
band ligation with sclerotherapy. 
One hundred patients with non-variceal AUGIB required endoscopic therapy. Of 
these patients, mono-therapy was used 53% (n=53) of the time; adrenaline alone 47% 
(n=47), endoscopic clip 3% (n=3), thermal therapy 3% (n=3). Dual therapy was used 
47% (n=47) of the time. 
 
3.3.8 Patient outcomes 
Rebleeding occurred in 8.9% of patients (n=42) and 3.2% required surgery (n=15). 
A total of 14.7% of patients died during the index admission (n=69). These patients 
were older than those who survived admission (70.4±15.1 years versus 62.9±19.2 
years; P=0.002).  
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3.3.9 Diurnal and seasonal variation of acute upper gastrointestinal bleeding 
To investigate for diurnal and seasonal variation of the presentation of AUGIB the 
day was split into equal 6 hour periods and 4 seasons as outlined in section 3.2. 
Monthly admission rates for AUGIB are shown in figure 3.4. This highlights a peak 
incidence during the month of October, after which admission rates decline in 
November and December. Lowest admission rates were found in February. No 
difference was observed between the monthly admission rate (χ2=17.05, P=0.106). 
However, when examining the seasonal admission rates fewer admissions were 
observed during the three winter months (χ2=9.10, P=0.028) (see figure 3.5).  
Admission rates throughout the 24-hour period are shown in table 3.12. There is 
significant variation throughout the day with a higher proportion of patients admitted 
during the 1201-1800 time period (χ2=18.83, P<0.001). 
 
Rockall and Glasgow Blatchford scores of patients, for the 4 time periods of the day, 
were analysed to determine whether or not ‘sicker’ patients presented at any specific 
time point. Differences were observed between time of admission and Rockall score 
(p=0.048). Patients have a significantly higher median Rockall score during the 
06:01-1200 (median Rockall score=3) time period when compared to 12:01-18:00 
(median Rockall score=2) period (P=0.006). No diurnal difference was observed for 
the Glasgow Blatchford score (P=0.39). However, there is a clear linear trend starting 
from the 06:01-12:00 (median Glasgow Blatchford score=10) time period through to 
the 00:01-06:00 (median Glasgow Blatchford score=8) time period (P<0.01). There 
was no diurnal difference in in-hospital mortality (χ2=0.62, P=0.89) or 30 day 
mortality (χ2=3.06, P=0.38). These results are shown in table 3.12.  
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There was no difference in Rockall score (P=0.88) or Glasgow Blatchford score 
(P=0.39) over the four seasons. No difference was observed in the in-patient mortality 
between the four seasons (χ2=3.32, P=0.35) or 30-day mortality (χ2=3.03, P=0.39) – 
see table 3.13. 
 
Non-variceal AUGIB  
For non-variceal AUGIB, significant variation was seen in both seasonal and diurnal 
presentation. Presentation was more common in autumn (n=129) and lowest in winter 
(n=82) with these differences found to be significant (χ2=10.811, P=0.013). 
Presentation was more common in the 12:01-18:00 period (n=139) and lowest during 
00:01-06:00 (n=80) (χ2=16.925, P=0.001). 
No significant differences were seen in the seasonal Rockall (P=0.83) or Glasgow 
Blatchford scores (P=0.52). The Rockall score does show diurnal variation (P=0.003). 
As with the variceal and non-variceal groups combined this difference is observed 
between the 06:01-1200 (median Rockall score = 3) time period when compared to 
12:01-18:00 time period (P=0.003). However, the Glasgow Blatchford score does not 
show any variation (P=0.18). 
 
Variceal AUGIB  
No seasonal variation was observed in the presentation of variceal haemorrhage 
(χ2=2.522, P=0.471). A large proportion of variceal bleeds presented in the 12:01-
18:00 (n=16) time period. However, there is no significant diurnal variation 
(χ2=2.522, P=0.471). No significant differences were seen in the seasonal Rockall 
(P=0.31) or Glasgow Blatchford scores (P=0.39), nor in diurnal variation (Rockall: 
P=0.80; Glasgow Blatchford Score: P=1.0). 
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Table 3.9 Season of admission with acute upper gastrointestinal bleeding 
Season Percentage of patients (n=470) 
Spring 25.1 (n=118) 
Summer 25.5 (n=120) 
Autumn 29.6 (n=139) 
Winter 19.8 (n=93) 
 
 
 
 
 
Table 3.10 Time of admission and percentage of patients presenting during 6 
hour periods 
Time of admission Percentage of patients (n=470) 
0001 – 0600 19.1 (n=90) 
0601 – 1200 24.0 (n=113) 
1201 – 1800  33.0 (n=155) 
1801 – 0000 23.8 (n=112) 
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Table 3.11 Diurnal variability for Glasgow Blatchford and Rockall Scores and 
mortality 
 0001-0600 
(n=90) 
0601-1200 
(n=113) 
1201-1800 
(n=155) 
1801-0000 
(n=112) 
GBS 
Median (IQR) 
 
8 (4-12) 
 
10 (6-13) 
 
9 (5-12) 
 
9 (5-13) 
Rockall (Pre-
OGD) 
Median (IQR) 
 
2 (1-4) 
 
3 (1-4)* 
 
2 (1-3)* 
 
3 (1-4) 
In-Hospital 
Mortality (%) 
15.6 (n=14) 15.9 (n=18) 14.8 (n=23) 12.5 (n=14) 
30 Day 
Mortality (%) 
11.1 (n=10) 19.5 (n=22) 14.8 (n=23) 17.8 (n=20) 
*p=0.006 
 
 
 
Table 3.12 Seasonal variability for Glasgow Blatchford and Rockall scores and 
mortality 
 Spring 
(n=118) 
Summer 
(n=120) 
Autumn 
(n=139) 
Winter (n=93) 
GBS 
Median (IQR) 
 
9 (5-14) 
 
10 (6-14) 
 
9 (5-13) 
 
11 (7-14) 
Rockall (Pre-
OGD) 
Median (IQR) 
 
2 (1-4) 
 
3 (1-4) 
 
2 (1-4) 
 
2 (1-3) 
In-Hospital 
Mortality (%) 
11.0 (n=13) 19.2 (n=23) 13.7 (n=19) 15.1 (n=14) 
30 Day 
Mortality (%) 
11.9 (n=14) 20.0 (n=24) 16.5 (n=23) 15.1 (n=14) 
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Figure 3.4 Monthly admission with acute upper gastrointestinal bleeding 
Monthly admissions for AUGIB are shown. Note the lowest number of AUGIB 
occurred in June, December and February with the highest number in October. 
 
 
Figure 3.5 Seasonal admission with acute upper gastrointestinal bleeding  
Fewer patients are admitted during the winter months (Spring n = 118, Summer n = 
120, Autumn n = 139, Winter n = 93). 
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3.4 Summary and discussion 
This chapter examines the presentation and management of AUGIB. One interesting 
observation regards the use of scores to risk assess AUGIB. Only 20% of patients had 
a risk score documented which is very low given that it guides management and is 
considered mandatory by National and International guidelines (SIGN 2008; NICE 
2012; Gralnek et al 2015). Low risk patients can be considered for early discharge and 
outpatient endoscopy. 
The Glasgow Blatchford score performed better than the Rockall score in identifying 
patients at low risk for requiring an intervention (transfusion, endoscopic therapy, 
surgery) or dying. A patient with a Glasgow Blatchford score of ≤ 2 did not require an 
intervention in this population. In contrast, 13.8% of patients with a Rockall score of 
0 received a blood transfusion and 6.2% required endoscopic therapy. Given these 
findings the Glasgow Blatchford score should be used as the more accurate system in 
our local population for pre-endoscopy risk assessment. Indeed, the NICE guidelines 
on AUGIB endorse the preferential use of the Glasgow Blatchford score for pre-
endoscopic risk assessment. 
Current guidelines define low risk patients as a Glasgow Blatchford score of 0, and 
that these patients should be considered for early discharge and outpatient endoscopy 
(Sung et al 2011; NICE 2012). The data from this audit suggests that a Glasgow 
Blatchford score of ≤ 2 can be used to identify low risk patients. This accounts for 
14.7% of admissions compared to 6.0% who score 0 suggesting significantly more 
patients could be considered for early discharge. Indeed, several recent studies have 
investigated what can be considered as a low risk Glasgow Blatchford score, 
suggesting that a score of ≤ 2 could be used to define low risk patients (Masaoka et al 
2006; Stephens et al 2009; Srirajaskanthan et al 2010). An observational study over a 
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5 year period found that patients with a Glasgow Blatchford score of ≤ 2 and aged 
below 70 could be safely managed as an outpatient (McLaughlin et al 2012).  
In this chapter, it has been shown for the first time that there is a significant diurnal 
and seasonal variation in AUGIB in the UK population. Fewer admissions are seen in 
the winter months and a higher proportion of patients presented in the 12:01-18:00 
time period. In addition, a diurnal variation to the Rockall score was seen with a 
higher score being observed during the 06:01-1200 time period when compared to 
12:01-18:00. 
Diurnal and seasonal variations in AUGIB have been previously described but the 
data is conflicting. One European study found biphasic peaks in peptic ulcer bleeding 
(Minoli et al 1994). However, data from China has highlighted a diurnal variation in 
the presentation of AUGIB with a peak incidence in the night-time hours (Du et al 
2010). Several authors have investigated seasonal differences in AUGIB with 
conflicting results; results from China suggest higher rates during winter months 
whereas data from Greece suggests the opposite (Du et al 2010; Thomopoulos et al 
1997). Others have described higher rates in winter and autumn, or no variation at all 
(Benz et al 1993; Csendes et al 1995; Sezgin et al 2007; Stermer et al 1995; 
Zimmerman et al 1992).  
One previous study has reported a diurnal variation in the presentation of AUGIB, 
with symptom onset during the morning hours (Manfredini et al 1994). In the 
majority of the patients in this study, it is time of presentation to the hospital rather 
than symptom onset that was recorded, which may explain the peak presentation 
during the hours of 1201-1800. These results conflict with recent data from China, 
where more cases of AUGIB presented at night (Du et al 2010).  
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Previous reports have shown a diurnal variation of variceal bleeding in patients with 
cirrhosis, with higher rates in the evening and early morning (Mann et al 1999; 
Merican et al 1993; Siringo et al 1996). This has been explained by changes in portal 
blood flow throughout the day (Alvarez et al 1994). This study includes just 11% with 
variceal haemorrhage and as a result of these small numbers no diurnal variation was 
seen. 
A large proportion of patients in this study suffered from peptic ulcer bleeding 
(34.5%). These findings are consistent with previous studies that have demonstrated 
seasonal variation for the incidence of duodenal and gastric ulcers (Bendahan et al 
1992; Manfredini et al 2010; Savarino et al 1996; Shih et al 1993; Tenías Burillo et al 
2001; Tsai and Lin 1998). Diurnal variation has been previously described, and is 
thought to be related to circadian changes in gastric acid secretion, intragastric pH, 
pepsinogen and gastrin (Manfredini et al 1994; Moore & Halberg 1986; Saitoh et al 
2001; Tarquini et al 1987).    
Several authors have looked for seasonal differences in AUGIB with conflicting 
results. Results from China suggest an increased incidence during colder months 
(December to April) and similar results are also seen in Israel (Du et al 2010; Stermer 
et al 1995). The observation of a decrease in presentation during winter is consistent 
with a previous European based study (Thomopoulos et al 1997). This was thought to 
be due to higher use of salicylate drugs in the winter months, although later studies 
found opposing results (Langman 1964; Stermaer et al 1995; Zimmerman et al 1992). 
A study from Germany found no seasonal difference in peptic ulcer bleeding; 
however, other endoscopic diagnoses were not included in the analysis (Benz et al 
1993). Seasonal fluctuation has been thought to be due to the fluctuation of the 
incidence of duodenal ulcer (Zimmerman et al 1992). The difference between Europe 
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and Asia may be explained by differing patient characteristics and climate. Climate 
has been thought to play an important role in gastric ulcer bleeding with there being 
an inverse relationship between the number of gastric ulcers and mean temperature 
and mean vapour pressure (Nomura et al 2001).  
This is the first time that a diurnal and seasonal variation amongst AUGIB risk scores 
(i.e. Rockall and Glasgow Blatchford scores) and mortality has been investigated. 
Despite there being a statistically significant diurnal variation to Rockall scores and a 
linear trend of Blatchford score over a 24 hour period, it is unlikely that these findings 
are clinically relevant.  
This work has several strengths. Firstly, the analysis included all patients with 
AUGIB, which is more pertinent to real life practice. Secondly, the endoscopic 
diagnosis for all patients was known and recorded.  One weakness is one does not 
know the exact time of symptom onset but rather the time of presentation to the 
Emergency Department. Secondly, small numbers in some of the analyses may 
account for non-significant findings with regards to Rockall and Glasgow Blatchford 
scores and diurnal and seasonal variations. 
These results however, do support both a diurnal and seasonal variation in the 
presentation of AUGIB. The reasons for such differences remain unclear. This may 
have implications for the provision of endoscopy services. No evidence was observed 
to suggest that those patients presenting out of hours are any more unstable than those 
presenting during the daytime. The diurnal presentation means many patients are 
more likely to be clerked, resuscitated and made ready for upper GI endoscopy by the 
end of the working day. This is in contrast to many endoscopy units where morning 
lists are ring fenced for AUGIB.  Further studies are required to examine diurnal and 
seasonal variation in the UK AUGIB population. 
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CHAPTER 4 – PLATELET ACTIVATION AND 
PROTHROMBOTIC MARKERS IN NON-VARICEAL 
ACUTE UPPER GASTROINTESTINAL BLEEDING 
 
4.1 Introduction 
Acute upper gastrointestinal bleeding (AUGIB) is the most common 
gastroenterological emergency, a common reason for medical admissions and is 
associated with significant morbidity and mortality (Klein and Gralnek 2015). Studies 
have previously noted an excess of cardiovascular (CVS) events in patients who have 
suffered from an AUGIB (Hudson et al 1995). Patients who have aspirin withheld for 
8 weeks following admission with AUGIB have significantly higher rates of CVS 
events (Sung et al 2010b). 
It was hypothesised that significant changes in platelet activation and prothrombotic 
markers would be observed in patients undergoing AUGIB. 
 
4.2 Methods 
Patients presenting to hospital with AUGIB were recruited and compared with 
dyspeptic patients undergoing an OGD as controls. Only patients with non-variceal 
bleeding were recruited. Patients were excluded from the control group if upper 
gastrointestinal pathology was found (e.g. upper GI malignancy or other bleeding 
lesion). 
The methods for quantifying platelet activation and prothrombotic markers have been 
described in Chapter 2.  
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Statistical analysis 
Data is expressed as mean±SD for normally distributed parameters and median 
(interquartile range) for non-normally distributed parameters. Normality was tested 
using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Statistical significance, of the 
changes in platelet activation and prothrombotic markers, was determined by t-test, 
for normally distributed data, and Mann Whitney for non-normally distributed data. 
Analysis of related samples was determined by Wilcoxon Signed-Rank test. A value 
of p<0.05 was considered statistically significant. Statistical analysis was performed 
with SPSS 19.0 software.  
 
4.3 Results 
4.3.1 Baseline patient characteristics 
A total of 31 patients with AUGIB and 25 controls were recruited to the study. Of 
these patients, 23 and 18 completed 12 week follow up respectively.  
Baseline patient characteristics are documented in table 4.1. Patients suffering from 
an AUGIB had a mean age of 66.4±18.2 years and 67.7% were of male gender. The 
control group was well matched for age, gender, BMI and comorbidities. AUGIB was 
associated with significant changes in both systolic (P=0.05) and diastolic blood 
pressure (P=0.013) and heart rate (P<0.001) as compared to controls, indicating that 
these patients had significant enough bleeding to induce haemodynamic changes. 
Patients with AUGIB had significantly lower haemoglobin levels when compared to 
controls (P<0.001). 
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The diagnoses seen in the AUGIB group were mainly peptic ulceration (83.9%) with 
the other patients suffering from minor GI lesions. Endoscopic therapy was required 
in 54.9% of patients, which is higher than that seen in the general cohort of AUGIB 
(described in Chapter 3), in which only 27.7% required an intervention (table 4.2). 
This suggests that the patients recruited had significant episodes of bleeding. 
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Table 4.1 Baseline patient characteristics 
Characteristics AUGIB (n=31) Controls (n=25) P-value 
Age (years) 66.4 (18.2) 62.8 (6.1) 0.311 
Gender 
• Male 
 
67.7% (n=21) 
 
72% (n=18) 
 
0.730 
BMI (kg/m2) 26.4 (5.0) 28.1 (4.8) 0.197 
Systolic BP (mm Hg) 123 (26) 135 (18) 0.05 
Diastolic BP (mm Hg) 70 (15) 80 (14) 0.013 
Heart rate (beats per 
minute) 
92 (17) 75 (15) <0.001 
Co-morbidity 
• DM 
• HTN 
• IHD 
 
16 % (n=5) 
42% (n=13) 
13% (n=4) 
 
8% (n=2) 
36% (n=9) 
16% (n=4) 
 
0.361 
0.651 
0.742 
Medications 
• Aspirin 
• Clopidogrel 
• Prasugrel 
• PPI 
• NSAIDS 
• Steroids 
 
48.4% (n=15) 
3.2% (n=1) 
3.2% (n=1) 
19.4% (n=6) 
25.8% (n=8) 
3.2% (n=1) 
 
20% (n=5) 
4% (n=1) 
0 
64% (n=16) 
4% (n=1) 
0 
 
0.028 
* 
* 
<0.001 
0.027 
* 
Current smoker 22.6% (n=7) 20% (n=5) 0.815 
Laboratory 
• Hb (g/dL) 
• WBC (109/L) 
• Platelets (109/L) 
• eGFR 
 
8.8 (2.4) 
9.7 (3.2) 
265 (123) 
74 (16) 
 
14.3 (1.4) 
7.09  (2.5) 
223  (46) 
71 (11) 
 
<0.001 
0.002 
0.088 
0.24 
Data presented as mean (standard deviation) (analysed by t-test), or as number of 
subjects (analysed by chi-squared test). *analysis inappropriate.  
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Table 4.2 Endoscopic diagnosis and therapeutics administered in patients with 
acute upper gastrointestinal bleeding 
 Percentage (n=31) 
Diagnosis  
Duodenal ulcer 61.3% (19)  
Gastric ulcer 22.6% (7) 
Oesophageal ulcer 6.5% (2) 
Oesophagitis 3.2% (1) 
Gastric erosions 3.2% (1) 
Mallory Weiss tear 3.2% (1) 
Therapy  
Injection 51.6% (16) 
Clip 19.4% (6) 
Thermal 19.4% (6) 
Number of modalities used  
None 45.1% (14) 
Single 19.4% (6) 
Dual 29.0% (9) 
Triple 6.5% (2) 
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4.3.2 Platelet activation in acute upper gastrointestinal bleeding 
Patients with AUGIB, had higher levels of circulating percentage of platelets staining 
positive for CD62P (P=0.001) and dual staining for CD62P and PAC-1 (P=0.03), 
when compared with controls. These results suggest that during the index admission, 
higher levels of platelet activation were seen in patients with AUGIB. No changes 
were seen in the reactivity of blood in response to ADP. 
After 12 weeks, patients with an AUGIB had higher levels of circulating platelets 
with positive staining for CD62P (P<0.001) and dual staining for CD62P and PAC-1 
(P=0.003). Significant differences are also seen in platelets staining for PAC-1 after 
12 weeks (P=0.001). These results suggest prolonged changes in platelet activation 
following an admission with AUGIB, lasting for a minimum of 12 weeks. 
No differences were seen in the longitudinal levels of platelet activation, for patients 
with AUGIB, between index admission and 12 weeks. No differences were seen in 
patients undergoing diagnostic OGD with respect to platelet activation. These results 
suggest that levels of platelet activation are maintained for at least 12 weeks following 
an AUGIB and that undergoing a diagnostic endoscopy does not induce longitudinal 
changes in platelet activation. 
Results are shown in tables 4.3-4.6. 
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Table 4.3 Platelet activation at baseline in patients with acute upper 
gastrointestinal bleeding 
 AUGIB (n=31) Controls (n=25) P-value 
CD62P at rest 
• % 
• MFI 
 
18.3 (5.8) 
30.2 (2.5) 
 
13.9 (3.7) 
28.9 (1.6) 
 
0.001 
0.023 
PAC-1 at rest 
• % 
• MFI 
 
5.6 (1.6-9.6) 
32.2 (3.1) 
 
4.0 (2.3-5.6) 
32.5 (4.1) 
 
0.108 
0.777 
CD62P+PAC-1+ % 1.5 (0.7-2.2) 0.8 (0.5-1.2) 0.030 
    
CD62P after ADP  
• % 
• MFI 
 
67.9 (15.9) 
87.0 (24.8) 
 
63.1 (17.6) 
77.4 (27.0) 
 
0.288 
0.175 
PAC-1 after ADP 
• % 
• MFI 
 
73.2 (23.1) 
150.9 (71.4) 
 
77.4 (15.6) 
122.4 (46.8) 
 
0.488 
0.082 
CD62P+PAC-1+ % 
after ADP  
65.6 (45.3-85.8)  63.7 (51.7-76.7) 0.613 
Soluble P-selectin 
(ng/mL) 
26 (10) 32.6 (14.6) 0.074 
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Table 4.4 Platelet activation after 12 weeks in patients with acute upper 
gastrointestinal bleeding 
 AUGIB (n=24) Controls (n=18) P-value 
CD62P at rest 
• % 
• MFI 
 
17.4 (3.8) 
29.6 (3.6) 
 
12.9 (2.8) 
28.1 (0.8) 
 
<0.001 
0.047 
PAC-1 at rest 
• % 
• MFI 
 
7.0 (3.7) 
31.0 (3.4) 
 
4.0 (1.8) 
32.2 (3.7) 
 
0.001 
0.274 
CD62P+PAC-1+ % 1.3 (0.7-2.0) 0.7 (0.6-0.9) 0.003 
    
CD62P after ADP 
• % 
• MFI 
 
66.1 (14.7) 
72.5 (21.6) 
 
61.2 (9.7) 
59.5 (12.7) 
 
0.227 
0.020 
PAC-1 after ADP  
• % 
• MFI 
 
79.4 (14.6) 
131.2 (49.4) 
 
85.1 (9.7) 
115.1 (32.6) 
 
0.163 
0.238 
CD62P+PAC-1+% 
after ADP 
60.5 (17.0) 57.1 (10.2) 0.414 
Soluble P-selectin 
(ng/mL) 
33.5 (21.4) 27 (7.4) 0.414 
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Table 4.5 Longitudinal changes in platelet activation in patients presenting with 
acute upper gastrointestinal bleeding 
 Baseline (n=31) Week 12 (n=24) P-value 
CD62P at rest 
• % 
• MFI 
 
18.3 (5.8) 
30.2 (2.5) 
 
17.4 (3.8) 
29.6 (3.6) 
 
0.463 
0.509 
PAC-1 at rest 
• % 
• MFI 
 
5.6 (1.6-9.6) 
32.2 (3.1) 
 
7.0 (3.7) 
31.0 (3.4) 
 
0.950 
0.175 
CD62P+PAC-1+ % 1.5 (0.7-2.2) 1.3 (0.7-2.0) 0.639 
    
CD62P after ADP 
• % 
• MFI 
 
67.9 (15.9) 
87.0 (24.8) 
 
66.1 (14.7) 
72.5 (21.6) 
 
0.664 
0.028 
PAC-1 after ADP  
• % 
• MFI 
 
73.2 (23.1) 
150.9 (71.4) 
 
66.1 (14.7) 
131.2 (49.4) 
 
0.227 
0.238 
CD62P+PAC-1+% 
after ADP 
65.6 (45.3-85.8) 60.5 (17) 0.890 
Soluble P-selectin 
(ng/mL) 
26 (10) 33.5 (21.4) 0.023 
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Table 4.6 Longitudinal changes in platelet activation following OGD 
 Baseline (n=25) Week 12 (n=18) P-value 
CD62P 
• % 
• MFI 
 
13.9 (3.7) 
28.9 (1.6) 
 
12.9 (2.8) 
28.1 (0.8) 
 
0.386 
0.034 
PAC-1  
• % 
• MFI 
 
4.0 (2.3-5.6) 
32.5 (4.1) 
 
4.0 (1.8) 
32.2 (3.7) 
 
0.308 
0.823 
CD62P+PAC-1+% 0.8 (0.5-1.2) 0.7 (0.6-0.9) 0.098 
    
CD62P-ADP 
• % 
• MFI 
 
63.1 (17.6) 
77.4 (27.0) 
 
61.2 (9.7) 
59.5 (12.7) 
 
0.654 
0.006 
PAC-1-ADP  
• % 
• MFI 
 
77.4 (15.6) 
122.4 (46.8) 
 
85.1 (9.7) 
115.1 (32.6) 
 
0.054 
0.575 
CD62P+PAC-1+-
ADP % 
 63.7 (51.7-76.7) 57.1 (10.2) 0.992 
Soluble P-selectin 
(ng/mL) 
32.6 (14.6) 27 (7.4) 0.095 
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4.3.3 Prothrombotic markers in acute upper gastrointestinal bleeding 
Patients with AUGIB had higher levels of both d-dimer (P=0.011) and vWF 
(P<0.001), when compared to controls, during the index admission. There is a trend 
seen towards an increase in IL-6 in patients with AUGIB (P=0.074). After 12 weeks, 
significant elevations of vWF in the AUGIB group persisted (P=0.022). These results 
suggest significant changes in prothrombotic markers, in patients with AUGIB, persist 
for a minimum of 12 weeks and that suffering from AUGIB causes a proinflammatory 
response. 
The levels of prothrombotic markers changed over the 12 week study period in 
patients with AUGIB; levels decreased significantly for vWF (P<0.001) and IL-6 
(P=0.029) when compared to the index admission. Longitudinal changes were not 
seen with d-dimer during the study period. This suggests that AUGIB may induce an 
inflammatory response. The increases seen in WBC in patients with AUGIB support 
this theory. 
As expected no significant changes in d-dimer, vWF or IL-6 were seen in the control 
group over the 12 week study period. 
Results are shown in tables 4.7-4.10. 
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Table 4.7 Prothrombotic markers at baseline  
Marker AUGIB (n=31) Control (n=25) P-value 
D-dimer (µg)  1.0 (0.1-2.2) 0.8 (0.6-1.2) 0.011 
vWF (IU/dL)  145 (60) 99 (34) <0.001 
IL-6 (pg/mL)  12.4 (3.4-21.3) 4.0 (2.9-10.8) 0.074 
 
 
 
Table 4.8 Prothrombotic markers after 12 weeks 
Marker AUGIB (n=23) Control (n=20) P-value 
D-dimer (µg)  2.1 (1.0-3.3) 0.8 (0.7-0.9) 0.073 
vWF (IU/dL) 103 (24) 89 (10) 0.022 
IL-6 (pg/mL) 6.1 (1.1-13.4) 5.3 (1.8-8.9) 0.295 
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Table 4.9 Prothrombotic markers in patients with AUGIB at 0 and 12 weeks 
Marker Baseline (n=31) 12 weeks (n=23) P-value 
D-dimer (µg)  1.0 (0.1-2.2) 2.1 (1.0-3.3) 0.796 
vWF (IU/dL) 145 (60) 103 (24) <0.001 
IL-6 (pg/mL) 12.4 (3.4-21.3) 6.1 (1.1-13.4) 0.029 
 
 
 
Table 4.10 Prothrombotic markers in controls at 0 and 12 weeks  
Marker Baseline (n=25) 12 weeks (n=2) P-value 
D-dimer (µg)  0.8 (0.6-1.2) 0.8 (0.7-0.9) 0.108 
vWF (IU/dL) 99 (34) 89 (10) 0.126 
IL-6 (pg/mL) 4.0 (2.9-10.8) 5.3 (1.8-8.9) 0.212 
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4.4  Summary and discussion 
In this chapter, changes in platelet activation and prothrombotic markers, as a result of 
acute upper gastrointestinal bleeding, have been examined. The results are discussed 
below and some interesting conclusions have been drawn.  
An episode of acute upper gastrointestinal bleeding is associated with a loss of 
circulating blood volume, which leads to haemodynamic changes (SIGN 2008). This 
is noted in this study; those patients with AUGIB had a lower systolic and diastolic 
blood pressure, in addition to an increase in heart rate, compared to controls 
indicating a significant episode of bleeding had occurred.  
The main finding in this study was that patients with AUGIB, when compared with 
controls, have significantly higher circulating activated platelets, as measured by 
expression of CD62P and PAC-1. Patients with AUGIB also demonstrated increased 
fibrinolysis (increased d-dimer), increased vascular dysfunction (increased vWF) but 
no difference in inflammation (IL-6).  In addition, platelet activation and vascular 
dysfunction remained significantly higher in the AUGIB group 12 weeks after the 
initial admission. These findings cannot be explained by differences in patient 
characteristics as patients were; age, gender and BMI matched. No differences were 
seen in conditions associated with the development of cardiovascular disease such as 
diabetes, hypertension, known ischaemic heart disease and current smoking.  
Therefore the differences in platelet activation and vascular function are likely to be a 
direct consequence of the AUGIB itself. Nearly 50% of the patients with AUGIB 
were taking aspirin at the time of admission compared to only 20% of controls, and 
this may be a cause of their admission. Aspirin, being an anti-platelet agent, would 
have been expected to reduce the levels of platelet activation seen in the AUGIB 
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group. However, despite the higher levels of aspirin use, the AUGIB group had higher 
levels of platelet activation compared to controls, which means these results have 
much more importance.  Unfortunately, due to the small numbers within this study 
this could not be adjusted for. Other possible explanations for the differences seen in 
platelet activation could be patient comorbidities, however there was no significant 
difference in major cardiovascular risk factors such as current smoking, diabetes, 
hypertension and prior ischaemic heart disease. H. pylori status was not assessed in 
our patient cohort and could be a potential confounding factor; previous studies have 
found elevated platelet activation in patients positive for H. pylori and a decreased 
platelet count, although the numbers in these studies were small (Elizalde et al 1997, 
Yeh et al 2010). In addition H. pylori has been associated with cardiovascular disease, 
although this claim has been refuted (Danesh et al 1999, Zhu et al 2002).  
As noted in previous studies a significant proportion of patients who suffer with 
AUGIB have a history of cardiovascular diseases (IHD, cardiac failure and stroke) 
(Hearnshaw et al 2010a; Sung et al 2010b). These patients are often taking aspirin or 
other antiplatelet agents, as part of secondary prevention of further cardiovascular 
events, which puts them at risk of AUGIB initially. Antiplatelet agents are frequently 
stopped on patients presenting with AUGIB; with no real consensus on when they 
should be recommenced. A previous study showed that in such patients taking aspirin 
for secondary prevention the recommencement of aspirin for secondary prevention, 
once bleeding had been controlled, resulted in lower mortality rates than those who 
had aspirin withheld for 8 weeks (Sung et al 2010b). The authors speculated that 
AUGIB might lead to a higher mortality rate in those patients whose aspirin was 
withheld, because these patients are more vulnerable to atherothrombosis and 
therefore cannot tolerate bleeding well (Sung et al 2010b). A second study, 
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investigating the discontinuation of aspirin following peptic ulcer bleeding, found an 
almost 7-fold increase in risk of death or acute cardiovascular events compared to 
patients who continued aspirin during the first 6 months of follow up (Derogar et al 
2013). The results presented in this thesis have particular relevance to the 
aforementioned studies, as the majority of patients recruited to our study had peptic 
ulcer disease. A recent study concluded that the use of antiplatelet or anticoagulants 
were not associated with adverse outcomes in patients with non-variceal AUGIB 
(Solakoglu et al 2014; Teles Sampaio et al 2016). 
The results demonstrated in this study may, in part, explain the excess of 
cardiovascular mortality in these patients; that is, patients suffering from AUGIB have 
higher levels of platelet activation, and platelet activation is associated with 
cardiovascular diseases (Muller et al 1985; Tofler et al 1987). This, in combination 
with the cessation of antiplatelet agents is a second hit, in terms of risk of 
cardiovascular events.   
Patients with AUGIB had higher baseline levels of d-dimer (35% rise) and vWF (31% 
rise) with a trend towards higher levels of soluble P-selectin and IL-6 when compared 
with controls. vWF levels remained higher in patients with AUGIB than controls 12 
weeks following index admission. However, the level of vWF in AUGIB does 
significantly reduce between index admission and 12 weeks. There is a trend towards 
higher IL-6 levels in patients with AUGIB. In this patient group IL-6 levels decline 
significantly over the 12 week study period. 
Elevated d-dimer has been associated with a poor prognosis in patients with both 
variceal and non-variceal AUGIB (Gutiérrez et al 2001; Primignani et al 2008; Violl 
et al 1996). Although these markers have not been studied exclusively in the non-
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variceal AUGIB population. Elevated levels of d-dimer and vWF have previously 
been noted in patients with bleeding gastrointestinal angiodysplasia (Junquera et al 
2005).  
Elevated levels of d-dimer and vWF are associated with the occurrence of 
cardiovascular diseases such as stroke and myocardial infarction (Lowe and Rumley 
1999; Pradhan et al 2004; Ridker et al 1994; Wannamethee et al 2012). P-selectin 
levels are elevated in disorders of arterial thrombosis such as acute myocardial 
infarction, stroke and peripheral vascular disease (Ikeda et al 1994; Merten and 
Thiagarajan 2004;). IL-6 is also associated with the development of cardiovascular 
events (IL6R MR et al 2012; Miwa et al 2013; Ridker et al 2000). The elevation of d-
dimer and vWF in patients with AUGIB may explain the reason for recurrent 
cardiovascular events seen in this patient group.  
In this study, patients with AUGIB have a lower haemoglobin and elevated white 
blood cell count. There was a trend towards a higher platelet count in those with 
bleeding, which is in contrast to a previous study investigating platelets in 
gastrointestinal bleeding (Kringen et al 2011). 
The investigation of platelet activation and prothrombotic markers following AUGIB 
alone has not been studied in detail before. These results do however pose a dilemma 
for treating clinicians as it seems counterintuitive to continue a patient on what is the 
cause of the bleed in the first instance (i.e. the antiplatelet agent). A clinician’s first 
intuition may be to worry about further bleeding. This study suggests a mechanism to 
help explain the clinical risk of thrombosis, and enable clinicians to understand the 
rationale for antiplatelet agents despite a recent bleeding event. However, recent 
guidelines regarding AUGIB do suggest, on the basis of the current evidence, that 
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low-dose aspirin used for the secondary prevention of vascular events should be 
continued once haemostasis has been achieved (Gralnek et al 2015; NICE 2012; 
SIGN 2008). Those with more complicated anti platelet regimens, such as those 
having had recent angioplasty, require multidisciplinary input from both 
Gastroenterologists and Cardiologists regarding the risks and benefits of starting, or 
withholding, medication.  
The findings of this study are applicable to patients admitted with AUGIB to UK 
hospitals. The baseline demographics of the vast majority of patients being of male 
gender with a mean age of 66 years is similar to that found in the recent nationwide 
UK AUGIB audit (Hearnshaw et al 2010a). 
Further studies will be required on the risk of cardiovascular diseases, following an 
episode of AUGIB and the optimum timing to recommence antiplatelet therapy in this 
context.  
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CHAPTER 5 – ACUTE CORONARY SYNDROMES 
COMPLICATED BY BLEEDING 
 
5.1 Introduction 
In Chapter 4, AUGIB was found to be associated with increased levels of platelet 
activation. As previously discussed, bleeding during the treatment of acute coronary 
syndromes (ACS) is associated with poor outcomes (short- and long- term) due to 
recurrent cardiovascular events and death (Eikelboom et al 2006; Manoukian et al 
2007; Mehran et al 2009; Moscucci et al 2003; Rao et al 2005). Even bleeding 
classified as minor is associated with a poor outcome (Nikolsky et al 2009; Rao et al 
2005). It was hypothesised that an episode of clinically significant bleeding in patients 
with acute coronary syndromes caused a prolonged prothrombotic state, as evidenced 
by an increase in platelet activation and prothrombotic markers, which increases long 
term mortality. 
 
5.2 Methods 
Patients admitted to hospital with ACS complicated by bleeding were recruited. ACS 
without bleeding and stable coronary artery disease patients were used as controls. 
Bleeding in the context of ACS was defined according to the International Society on 
Thrombosis and Haemostasis criteria (e.g. symptomatic bleeding in a critical area 
such as intracranial, gastrointestinal, retroperitoneal, clinically observed haemorrhage 
or access site haematoma) or covert (drop in Hb of >2g or drop in Hb needing 
transfusion of 2 or more units of blood) (Schulman and Kearon 2005). The methods 
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for quantifying platelet activation and prothrombotic markers have been described in 
Chapter 2. 
 
Statistical analysis 
Data is expressed as mean±SD for normally distributed parameters and median 
(interquartile range) for non-normally distributed parameters. Normality was tested 
using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Statistical significance of the 
changes in platelet activation was determined by repeated measures ANOVA for 
normally distributed data and Kruskal-Wallis for non-normally distributed data. Post-
hoc analysis was performed using Tukey for normally distributed and Mann-Whitney 
U with Bonferroni correction for non-normally distributed data. A value of p<0.05 
was considered statistically significant. Statistical analysis was performed with SPSS 
19.0 software.  
 
5.3   Results 
5.3.1 Baseline characteristics 
A total of 16 patients with ACS complicated by bleeding were recruited (index 
group). These were matched with 30 patients with ACS not complicated bleeding and 
29 patients with stable coronary artery disease (control groups). Of the initial 16 
patients in the index group, 9 completed 12 week follow up. Of the control groups 25 
patients in the ACS group completed 12 week follow up. Those in the stable coronary 
141 
 
artery disease group had blood taken at the initial time point only, as platelet 
activation was felt unlikely to vary during the period of follow up. 
Baseline characteristics are shown in table 5.1. Patients with ACS complicated by 
bleeding had a mean age of 65.9±12.5 years with 81.3% being of male gender. 
Significant haemodynamic changes were seen between groups. Post hoc analysis 
showed that patients with ACS complicated by bleeding had a lower systolic blood 
pressure, as compared with those patients with uncomplicated ACS (P=0.01) and a 
higher heart rate when compared to stable coronary artery disease patients (P=0.01). 
Patients with ACS complicated by bleeding, also had a lower platelet count when 
compared to both control groups (P=0.03). However, patients with stable coronary 
disease had lower WBC when compared to both groups (P<0.001). 
The types of bleeding observed in the index group were as follows; gastrointestinal 
bleeding, access site haematoma, and covert (i.e. 2 g/dL drop in haemoglobin) with 
the most common being access site haematoma and gastrointestinal bleeding – see 
table 5.2. 
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Table 5.1 Baseline patient characteristics 
Characteristics ACS & 
Bleed 
(n=16) 
ACS (n=30) SCD (n=29) P-value 
Age (years) 65.9 (12.5) 63.8 (11.6) 61.6 (8.5) 0.42 
Gender 
• Male 
 
81.3% 
(n=13) 
 
86.7% 
(n=26) 
 
75.9 (n=22) 
 
0.51 
BMI (kg/m2) 25.1 (3.7) 27.2 (4.8) 27.4 (4.3) 0.22 
Systolic BP (mm Hg) 124 (29) 146 (23) 135 (18) 0.01  
Diastolic BP (mm Hg) 75 (18) 83 (14) 75 (13) 0.06 
Heart rate (beats per 
minute) 
82 (24) 77 (14) 68 (12) 0.01  
Laboratory 
• Hb (g/dL) 
• WBC (109/L) 
• Platelets (109/L) 
• eGFR 
 
13.3 (3.0) 
9.3 (2.4) 
169 (56) 
64 (23) 
 
14.1 (1.6) 
10.3 (2.8) 
257 (69) 
70 (15) 
 
13.8 (1.6) 
6.9 (1.8) 
220 (54) 
74 (16) 
 
0.35 
<0.001 
0.03 
0.19 
 
Post hoc analysis: 
For systolic BP: differences between bleed/ACS and ACS 
For heart rate: difference between bleed/ACS and SCD 
For WBC: difference between ACS and SCD and Bleed and SCD 
For Platelets: difference between Bleed and ACS 
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Table 5.2 Nature of bleeding episode in patients with acute coronary syndromes 
Nature of bleed Percentage of patients 
Vascular access site bleed 37.5 (n=6) 
Gastointestinal bleeding 37.5 (n=6) 
≥ 2 g/dL drop in haemoglobin 25 (n=4) 
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5.3.2 Platelet activation and prothrombotic markers in acute coronary 
syndromes complicated by bleeding 
Significant differences in platelet activation were seen across the study groups during 
the index admission. Patients with ACS complicated by bleeding and patients with 
ACS, had higher levels of circulating percentage of platelets staining positive for 
CD62P, when compared to patients with stable coronary disease (P=0.001). No 
differences were seen in PAC-1 or dual positivity for CD62P and PAC-1. Significant 
changes were also seen in the response to ADP. Patients with ACS complicated by 
bleeding and patients with ACS had a significantly lower response to ADP, when 
compared to those patients with stable coronary disease; these changes were for 
percentage of platelets staining positive for CD62P (P=0.035), PAC-1 (P=0.002) and 
dual positivity for CD62P and PAC-1 (P=0.001). No differences were observed 
between patients with ACS complicated by bleeding and patients with ACS. 
With respect to prothrombotic markers, there were significant differences in the levels 
of vWF seen during the index admission. Higher levels of vWF were observed in 
patients with ACS complicated by bleeding and patients with ACS when compared to 
stable coronary disease controls (P<0.001). No significant differences were seen after 
12 weeks. 
At baseline, and after 12 weeks, no significant differences were seen with any 
prothrombotic markers or markers of platelet activation.  
These results can be seen in tables 5.3-5.6. 
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Table 5.3 Baseline platelet activation 
 ACS & Bleed 
(n=16) 
ACS (n=30) SCD (n=29) P-value  
CD62P at rest 
• % 
• MFI 
 
21.9 (11.6) 
30.1 (3.0) 
 
18.7 (5.9) 
29.1 (1.5) 
 
14.1 (4.4) 
29.0 (2.1) 
 
0.001 
0.121 
PAC-1 at rest 
• % 
• MFI 
 
2.2 (0.8-3.7) 
31.2 (4.3) 
 
3.1 (1.4-4.9) 
30.6 (2.9)  
 
2.8 (1.6-4.0) 
31.9 (3.2) 
 
0.383 
0.393 
CD62P+PAC-1+% 0.6 (0.3-1.0) 0.90 (0.3-1.6) 0.7 (0.4-0.9) 0.680 
     
CD62P after ADP 
• % 
• MFI 
 
34.4 (11.9) 
43.8 (11.3) 
 
35.3 (16.2) 
46.8 (20.3) 
 
51.8 (24.8) 
68.1 (27.1) 
 
0.035 
0.003 
PAC-1 after ADP  
• % 
• MFI 
 
31.4 (21.0) 
53.5 (18.6) 
 
37.0 (25.0) 
60.3 (33.4) 
 
60.2 (29.0) 
115.8 (71.5) 
 
0.002 
0.001 
CD62P+PAC-1+% 
after ADP  
11.8 (6.8-16.8) 15.7 (6.1-25.2) 41.4 (13.4-69.4) 0.001 
Soluble P-selectin 
(ng/mL) 
25.8 (8.8) 29.1 (12.2) 26.22 (6.7) 0.802 
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Posthoc analysis: 
CD62P: difference between bleed and SCD, and ACS and SCD. 
CD62P-ADP (% and MFI): differences between bleed and SCD, and ACS and SCD. 
PAC-1-ADP (% and MFI):  differences between bleed and SCD, and ACS and SCD. 
CD62P and PAC-1-ADP: differences between bleed and SCD, and ACS and SCD. 
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Table 5.4 Platelet activation at 12 weeks 
 ACS & Bleed 
(n=9) 
ACS (n=25) SCD (n=29) P-value  
CD62P 
• % 
• MFI 
 
15.4 (5.4) 
28.4 (1.1) 
 
17.4 (5.4) 
29.2 (2.0) 
 
14.05 (4.38) 
29.0 (2.1) 
 
0.053 
0.640 
PAC-1  
• % 
• MFI 
 
3.2 (1.3) 
30.8 (2.3) 
 
4.2 (2.3-6.1) 
31.6 (4.1) 
 
2.8 (1.6-4.0) 
31.9 (3.2) 
 
0.130 
0.655 
CD62P+PAC-
1+% 
0.7 (0.2) 1.1 (0.7-1.5) 0.7 (0.4-0.9) 0.065 
     
CD62P-ADP 
• % 
• MFI 
 
40.3 (24.4) 
51.4 (21.4) 
 
41.6 (19.0) 
52.0 (24.9) 
 
51.8 (24.8) 
68.1 (27.1) 
 
0.246 
0.051 
PAC-1-ADP  
• % 
• MFI 
 
49.2 (27.2) 
85.9 (47.6) 
 
51.5 (22.0) 
74.6 (30.1) 
 
60.2 (29.0) 
115.8 (71.5) 
 
0.317 
0.115 
CD62P+PAC-
1+ 
% after ADP  
23.9 (0.0-49.0) 23.5 (9.0-37.9) 41.4 (13.4-69.4) 0.301 
Soluble P-
selectin (ng/mL) 
26.8 (11.7) 26.9 (8.3) 26.22 (6.7) 0.993 
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Table 5.5 Prothrombotic markers at baseline  
Marker ACS & bleed 
(n=16) 
ACS (n=30) SCD (n=29) P-value 
D-dimer (µg)  2.6 (1.1) 2.56 (2.13-2.99) 2.73 (2.13-3.34) 0.641 
vWF (IU/dL)  141.0 (45.1) 131.6 (45.7) 87.5 (17.8) <0.001 
 
Post hoc analysis: 
vWF: No difference between ACS&bleed and ACS, P<0.001 for bleed and SCD and 
also for ACS and SCD 
 
 
 
Table 5.6 Prothrombotic markers after 12 weeks 
Marker ACS & bleed 
(n=9) 
ACS (n=25) SCD (n=29) P-value 
D-dimer (µg)  2.5 (1.1) 2.60 (2.01-3.19) 2.73 (2.13-3.34) 0.824 
vWF (IU/dL)  94.7 (16.7) 97.6 (25.7) 87.5 (17.8) 0.210 
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5.4 Summary and Discussion  
In this chapter, changes in platelet activation and prothrombotic markers, as a result of 
bleeding in the context of acute coronary syndromes have been examined. This is the 
first study to investigate platelet activation and prothrombotic markers in this setting. 
In patients presenting with ACS, and ACS complicated by bleeding, there are higher 
levels of platelet activation as evidenced by increased CD62P when compared to 
controls with stable coronary artery disease. This is an expected finding. In addition, 
there was a reduced platelet activity in these groups for ADP-stimulation when 
compared to stable coronary disease controls. These results are in contrast to those 
seen in the AUGIB group and could have several explanations. Firstly, PAC-1 
recognises an epitope on the GP IIb/IIIa complex on activated platelets at or near the 
platelet fibrinogen receptor. Clearly, any medication that interferes with this receptor 
will therefore have an impact on results. Patients with ACS are treated with powerful 
antiplatelet agents including GP IIb/IIIa inhibitors (e.g. tirofiban). Other medications 
used to treat ACS will also impact on platelet activation and reactivity and thrombotic 
markers, notably aspirin, thienopyridine/P2Y12 inhibitors (clopidogrel, prasugrel, 
ticlopidine and ticagrelor), heparin and direct thrombin inhibitors.  Patients admitted 
with ACS are a diverse group of patients and often undergo varying treatment 
strategies, depending upon individual patient characteristics. In those patients with 
ACS complicated by bleeding a proportion continued on these medications whereas 
some had the offending or contributory medications stopped for a brief period. Given 
the small numbers involved in this study it would be difficult to comment on whether 
the continuation or cessation of offending medications had any effect on the results 
observed. 
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Secondly, it could be that in contrast to patients suffering from AUGIB, excess 
platelet activation is not the cause of recurrent cardiovascular events. Several other 
reasons for poor outcomes have been suggested; discontinuation of antiplatelet agents, 
adverse effects of blood transfusion, adverse effects of hypotension and interventions 
required to control bleeding (Hamm et al 2011; Spencer et al 2007; Eikelboom et al 
2006; Fitchett et al 2007; Manoukian et al 2007; Mehran et al 2009; Disney et al 
2011). 
No differences were observed in platelet activation or reactivity to ADP after 12 
weeks of follow up. This may be due to the fact that changes in platelet activation in 
these patients do not differ. However, an alternative explanation would be that 
insufficient numbers of patients were recruited and followed up. Patients with ACS 
complicated by bleeding, were uncommon during the study period and difficult to 
recruit. One of the reasons for the paucity of this group of patients was due to a 
change in practice by many Cardiologists who began to use radial access 
preferentially over femoral access for coronary angiography. Previously many 
bleeding episodes in patients with ACS were at the access site, and the change of 
practice to using radial has resulted in lower rates of access site bleeding, need for 
transfusion and mortality (Bavishi et al 2016; Nathan and Rao 2012; Piccolo et al 
2014; Rajani et al 2015; Ruiz-Rodriguez et al 2016; Valgimigli et al 2015). The data, 
however, is conflicting with one recent study found that major bleeding events have 
increased over the past 10 years, although vascular access site bleeding did not impact 
on mortality (Sabbag et al 2015). Further studies have also shown that mild-moderate 
vascular access site bleeding (using GUSTO definitions) does not increase risk of 
adverse outcomes (Kikkert et al 2014; Vavalle et al 2013). In addition to this, 
bleeding has become more widely recognised as have poorer short and long term 
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outcomes and therefore the treatments decision were made with the potential side 
effect of bleeding borne in mind. 
Other factors may have played a part in poor patient numbers. Patients with ACS and 
bleeding have a prolonged hospital stay, often resulting in additional interventions to 
treat bleeding. These patients are monitored closely, which involves repeated 
venepuncture. Unfortunately, as a result of this a proportion of patients were 
unwilling to participate in this study. In addition to the problems with recruitment 
there were also problems with patient follow up. Of those patients with ACS 
complicated by bleeding that were recruited, 7 were unwilling to undergo repeat 
venepuncture after 12 weeks; this represents a drop out of approximately 44%. This 
appears to be a reflection of the general sickness and co-morbidity of this patient 
group, as only 17% of those patients with ACS without bleeding did not complete 
follow up. 
The female gender has a greater risk of bleeding in the context of ACS. However, in 
this study, the majority of those recruited were male. This could impact on these 
results although one recent study showed that it is the bleeding complication rather 
than gender that explains excess mortality (Ng et al 2016).  
Patients in this study with ACS and bleeding had an elevated WBC as compared to 
controls. This phenomenon has been noted previously and is an independent predictor 
of major bleeding, in addition to 1 year mortality (Palmerini et al 2011; Palmerini et 
al 2013). 
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CHAPTER 6 – CONCLUSIONS AND FUTURE WORK 
 
 
The results from Chapter 3 show that the use of pre-endoscopy risk scores is 
disappointingly low (20%).  This is despite the fact the current guidelines suggest that 
these scores are a mandatory part of the initial assessment of patients with AUGIB, 
and that patients with a GBS of zero can be discharged early with an urgent outpatient 
endoscopy. In this study, it was found that patients with a GBS ≤ 2 did not require an 
intervention and did not die. A GBS ≤ 2 accounted for approximately 15% of patients 
in this study population, however; further larger studies are required to demonstrate 
that those patients with a GBS ≤ 2 could be safely managed on an outpatient basis. 
It was also found that there is both a diurnal and seasonal variation in the presentation 
of AUGIB, although the reasons for such differences remain unclear. These findings 
may have implications for the provision of endoscopy services. No evidence was 
observed to suggest that those patients, presenting out of hours, are any more unstable 
than those presenting during the daytime. The diurnal presentation means many 
patients are more likely to be clerked, resuscitated and made ready for upper GI 
endoscopy by the end of the working day. This is in contrast to many endoscopy 
units, where morning lists are ring fenced for AUGIB.  Further studies are required to 
examine diurnal and seasonal variation in the UK AUGIB population and therefore 
allow better endoscopy provisions in the future. 
The work described in Chapter 4 demonstrates that AUGIB is associated with 
increased levels of platelet activation and the prothrombotic markers d-dimer and 
vWF. Work in Chapter 5 shows that patients who suffer from a bleeding episode, 
during treatment for ACS, have a higher level of platelet activation than stable 
coronary disease controls. Although no differences were observed between the ACS 
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with bleeding and ACS groups, longitudinal studies are required to see if platelet 
activation is prolonged in the ACS with bleeding group. Further studies are also 
needed to address the problem of adverse outcomes in patients that suffer from 
bleeding during the treatment of ACS. 
Overall, these studies show that there is a higher level of platelet activation in patients 
suffering from AUGIB. These are novel findings. In addition, those with AUGIB had 
higher levels of d-dimer and vWF. These findings may explain the increased risk of 
cardiovascular events seen in patients with AUGIB. Patients presenting with AUGIB 
have prolonged levels of platelet activation for at least 12 weeks following the index 
event. This phenomenon may be further prolonged and further studies are required to 
examine this. In patients with high cardiovascular risk, earlier, and bolder, re-
introduction of antiplatelet therapy should be initiated. More in depth studies will be 
required on the risk of cardiovascular diseases following an episode of AUGIB and 
the optimum timing to recommence antiplatelet therapy in this context. These studies 
could include larger numbers, examining the length of change in platelet activation 
and prothrombotic markers, and whether the early reintroduction of anti-platelet 
agents can alter this response.  
This work highlights several unresolved questions that will require future studies to 
address the following issues. In patients with AUGIB, it is unclear for how long the 
higher levels of platelet activation and prothrombotic markers is a phenomenon for, 
and whether the early re-introduction of anti-platelet agents will make a difference on 
long term outcomes; it seems apparent that this strategy improves outcomes in the 
short-term. In patients with AUGIB it is unclear whether the differences we have seen 
are clinically relevant; although it would appear from previous studies showing the 
cardiovascular risk that they are. Unfortunately, in patients with bleeding during an 
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episode of ACS this study does not resolve the reasons behind their poor outcome; 
high drop out rates and difficulties in patient recruitment affected the results and 
larger studies are required to investigate further.  
To conclude, the work in this thesis supports the use of the pre-endoscopy risk scores 
in patients with AUGIB, preferentially the Glasgow Blatchford score, and that there is 
a diurnal and seasonal variation in the presentation of AUGIB. In addition, patients 
with AUGIB have been shown to have higher levels of platelet activation (as 
measured by CD62P and PAC-1), and prothrombotic markers (increased vascular 
dysfunction and increased fibrinolysis), for a period of at least 12 weeks, which has 
treatment implications. Finally, and unfortunately, no such changes were seen to 
explain the poor outcomes in patients with ACS complicated by bleeding, although 
this may be due to problems with recruitment. 
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